Diffusing Innovations Under Market Competition: Evidence from Drug-Eluting Stents

Ginger Zhe Jin[1], Hsienming Lien[2], and Xuezhen Tao*[3]

[1]University of Maryland & NBER
[2]National Chengchi University & CIER
[3]Shanghai University of Finance and Economics

January 21, 2026

Abstract

This paper examines how hospital competition and insurance reimbursement policies shape the diffusion of medical innovations. Using patient-level data from Taiwan's drug-eluting stent (DES) market in the Taipei area, we estimate a structural model that integrates patient demand with hospitals' endogenous portfolio and pricing decisions. We document a fundamental trade-off: intensified competition reduces prices but weakens hospitals' incentives to adopt new technologies. Counterfactual simulations that vary market structure and incorporate selective contracting or targeted patient coupons show that the effectiveness of reimbursement policies depends critically on hospitals' strategic responses and the surrounding competitive environment.

JEL: D4, I18, L13, O33.

Keywords: drug-eluting stents (DES), technology diffusion, hospital competition, selective contracting, reimbursement policy.

*We thank Leila Agha, Jeffrey Macher, Pierre Bodéré, Andrew Ching, Lucy Wang, and seminar and conference participants at the National Taiwan University, Research Center for Humanities and Social Sciences at Academic Sinica, Shanghai University of Finance and Economics, the 2024 Annual Health Econometrics Workshop, the 2024 Asian-Pacific Industrial Organization Conference, the 2025 International Industrial Organization Conference, the 2025 DC-IO day, Georgetown University, University of Illinois at Urbana-Champaign, University of Pennsylvania, Purdue University and the 2026 ASSA meetings for constructive comments. Our data was generously provided by the National Health Insurance Database of Taiwan. Lien appreciates financial support from the Ministry of Science and Technology (Grant no: MOST 108-2410-H-004-027-MY2). All rights reserved. All errors are ours.

1 Introduction

Rising health expenditure poses a critical challenge for economies worldwide, with the diffusion of new medical technologies as a primary driver of both improved outcomes and rising costs (Chernew and Newhouse (2011), Chandra and Skinner (2012), Skinner and Staiger (2015), Dunn, Fernando and Liebman (2023), Dunn, Fernando and Liebman (2024)). This dual impact creates a fundamental policy trade-off: promoting timely access to valuable innovations while maintaining the sustainability of health spending. While governments employ reimbursement design and market-structure regulation as the principal levers to navigate this trade-off, the effectiveness of these policies is not automatic (Nexon and Ubl (2010), McClellan (2011), Chandra, Flack and Obermeyer (2024)) Their ultimate impact is mediated by the strategic responses of healthcare providers—most notably hospitals and doctors—who act as the crucial intermediaries between innovation and patient access (Chandra, Cutler and Song (2011)). Understanding the behavior of these downstream agents is therefore paramount to designing effective health policy.

As gatekeepers, these intermediaries translate the potential of a new technology into realized market outcomes. Their strategic choices on whether, when, and at what price to offer new products are shaped by a complex interplay of economic forces. Operating in local markets, they face competitive pressures from rival providers, heterogeneous demand from patients, and the specific constraints and opportunities embedded in reimbursement rules. These forces govern their core decisions on technology adoption and pricing, which in turn can accelerate or delay diffusion and ultimately determine the allocation of surplus among patients, providers, manufacturers, and the public payer.

To investigate the role of intermediaries, we analyze the cardiac stent market in Taipei, Taiwan. Before bare metal stents (BMS), balloon angioplasty was used to compress arterial plaque, but this method lacked long-term effectiveness. BMS improved outcomes by keeping arteries open, yet caused in-stent restenosis in 20–30% of patients due to scar tissue formation. Drug-eluting stents (DES) addressed this issue by releasing medication to inhibit scar growth, offering superior clinical benefits at a higher cost (Tu et al. (2007), Kandzari et al. (2017)). Further advancements in DES technology—-such as the use of stronger alloys (e.g cobalt-chromium), ultrathin struts, and more biocompatible drugs (e.g. Zotarolimus)—-have significantly reduced the risk of stent thrombosis, making newer generations of DES a major improvement over earlier stent models (Navarese et al. (2014), Kandzari et al. (2017), Bangalore et al. (2018)).[1]

This market of analysis operates within the framework of Taiwan's National Health Insurance (NHI), a universal coverage system that provides an ideal empirical context for our research. Three

[1]For instance, Navarese et al. (2014) shows that the new generation DES demonstrated a 22% reduction in the odds of myocardial infarction compared with the old generation devices, without increasing mortality. Among these, everolimus-eluting stents (EES) significantly lowered the risk of stent thrombosis compared to paclitaxel-eluting stents (PES). While both generations showed comparable efficacy against restenosis, EES stands out as the safest option.Bangalore et al. (2018) shows that newer ultrathin-strut drug-eluting stents (DES) reduce target lesion failure (TLF) by approximately 16% at one year.Kandzari et al. (2017) employs randomized 1,334 patients and found that the third-generation stent (ultrathin struts, bioresorbable polymer) was superior to the second-generation Xience stent (thin struts, durable polymer) for the primary endpoint of target lesion failure at 12 months (6.2% vs. 9.6%).

features of this setting are particularly salient. First, the Taipei area is a decentralized, competitive hospital market where numerous providers make portfolio choices. This allows us to observe a rich set of strategic decisions as hospitals decide whether to *adopt* a new manufacturer's brand or *upgrade* an existing one. Second, Taiwan NHI's "top-up" reimbursement policy creates a stark financial trade-off for patients: BMS are fully covered and effectively free, while DES require large out-of-pocket payments in addition to NHI's base stent reimbursement to hospitals. This payment policy directly shapes patient demand, constrains hospital pricing and, more importantly, influences hospitals' decision to adopt new DES. Third, two system-wide, exogenously timed cuts to the base stent reimbursement provide valuable shocks to hospital margins, aiding the identification of supply-side responses.

This rich institutional setting enables us to formalize and investigate our central research question: how do market structure and reimbursement design jointly shape hospitals' technology adoption and pricing decisions, and what are the resulting equilibrium effects on patient welfare, provider profits, and public spending? Answering this question poses a significant analytical challenge. The observed market outcomes—prices, technology availability, and patient choices—are equilibria resulting from the interaction of latent patient demand and strategic hospital supply. A hospital's incentive to invest in a new technology, for instance, depends on its expectations of patient demand and the competitive responses of its rivals. To disentangle these interdependent forces and recover the underlying behavioral and cost parameters, a structural approach is required.

Our analysis proceeds by developing and estimating a structural model of the Taipei DES market. We specify a discrete-choice model for patient demand that accommodates rich heterogeneity in preferences for clinical novelty, price, and hospital characteristics, using a mixed logit formulation. On the supply side, we model hospitals as strategic agents in a two-stage quarterly game. In the first stage, they make a portfolio decision—whether to adopt a new brand, upgrade an existing one, or maintain the status quo—weighing expected profits against the fixed costs of adjustment. In the second stage, conditional on the market-wide portfolio configuration, hospitals engage in Bertrand-Nash pricing competition.

To identify the parameters of this model, we combine a unique set of datasets. The core of our analysis is built on individual-level inpatient claims, which provide granular information on patient demographics, clinical conditions, and the specific stent choices made. Crucially, we supplement these administrative records with a manually collected hospital-model-time panel of the exact out-of-pocket prices faced by patients. To account for socioeconomic heterogeneity, we merge these files with township-level data on average household reported taxable income. This fusion of clinical, pricing, and income data provides the rich empirical foundation necessary to estimate our model.

The model is estimated via simulated maximum likelihood, with a control-function approach to address the endogeneity of prices. Our demand-side estimates reveal the core tension facing providers: patients are price-sensitive, particularly those with lower income or greater comorbidity, but simultaneously place a substantial premium on access to the "newest-generation" technologies. On the supply side, the estimates for the fixed-cost parameters provide direct evidence on the eco-

nomics of diffusion, confirming that upgrading an existing product line is significantly less costly for a hospital than adopting an entirely new brand, which rationalizes the observed path of technology diffusion.

The estimated model provides a rich framework for quantitatively evaluating alternative policy regimes. We conduct two sets of counterfactual simulations. First, we analyze the interplay of market structure and patient demand. Simulating equilibria under varying numbers of competing hospitals reveals a fundamental trade-off: while more intense competition disciplines prices and benefits consumers, it also erodes hospital profit margins, thereby weakening the incentive to invest in frontier technologies. Counterfactual simulations show that, as the number of hospitals increases, intensified price competition dominates reduced adoption incentives, leading to a net gain in consumer surplus and total welfare. We also find that strong patient preferences for "newness" act as a powerful demand-side pull for innovation, but the distribution of the resulting surplus gains between patients and hospitals depends critically on the intensity of competition.

Second, we evaluate the effectiveness of alternative reimbursement designs. A supply-side policy of selective contracting, in which the NHI leverages its bargaining power to negotiate wholesale price discounts with specific manufacturers in exchange for exclusive reimbursement, can generate a "quadruple win"—benefiting consumers, hospitals, participating manufacturers, and the payer. However, we find that this outcome is most robust in concentrated markets, where exclusive contracts allow hospitals to retain sufficiently large rents to justify upgrading their DES portfolios. In more competitive markets, by contrast, rent dissipation limits the policy's leverage.

Increasing the NHI's DES-specific reimbursement rate (applied uniformly across all DES models) has the opposite pattern: it is most effective in boosting DES utilization in competitive markets, where high pass-through rates lead to price reductions but the policy also imposes a substantial fiscal burden on the insurer. Alternatively, a demand-side patient coupon targeting low-income individuals can improve equity with limited market-wide effects when the size of the program is not sufficiently large or the market is competitive enough so that hospitals have minimal incentives to adjust prices or product offerings. When more patients are eligible for patient coupons, hospitals—especially those facing less market competition—have a stronger incentive to raise the list price for all patients, which subsequently hurts unsubsidized patients and entails more government spending to fund patient coupons.

Taken together, these findings highlight the importance of accounting for hospitals' strategic responses and market structure when designing policies to promote the diffusion of medical innovations.

1.1 Related Literature

Our research contributes to six main strands of economic literature. First, our work speaks directly to the classic industrial organization literature on the relationship between market competition and innovation. While the foundational debate—from Schumpeter (1942) and Arrow (1962) to modern theoretical and empirical analyses such as Aghion et al. (2005)—has centered on the in-

centives for R&D investment at the producer level, we shift the analytical focus to the *diffusion of innovations by intermediaries*. In our setting, hospitals act as downstream agents who face strategic trade-offs analogous to those of upstream innovators, including the cannibalization of existing product lines and business stealing from rivals (Berry and Waldfogel, 1999; Mankiw and Whinston, 1986). By modeling and quantifying these forces at the intermediary level, we show how portfolio choice—specifically, the discrete decision to adopt a new brand versus upgrade an existing one—becomes the key strategic margin governing the speed and scope of diffusion.

Second, we build upon the literature on the diffusion of medical technologies. Prior work has identified numerous determinants of technology adoption, including intellectual property regimes (Kyle, 2007), social learning among physicians (Conley and Udry, 2010), and the potential for new technologies to exacerbate health disparities (Skinner and Staiger, 2015). Our primary contribution here is to model the *hospital*, rather than the individual physician, as the key strategic decision-maker. By structurally modeling the hospital's portfolio choice, we endogenize the availability of new technologies to patients at the market level. This framework allows us to distinguish between the distinct economic considerations of adopting an entirely new brand versus upgrading an existing one, revealing how patient preferences for "newness" are transmitted through hospital incentives to shape market-wide diffusion paths, a dynamic also explored in studies of consumer learning (Ching, Erdem and Keane, 2013; Collard-Wexler, Grennan and Steck, 2024).

Third, our paper contributes to the research on provider responses to reimbursement policies. A rich body of work has documented a wide range of behavioral responses to payment design, including patient upcoding (Dafny, 2005), adjustments to treatment intensity (Jin, Lien and Tao, 2025), and quality investment decisions driven by payer mix (Garthwaite, Ody and Starc, 2022). We highlight a complementary and economically significant channel: the strategic management of technology portfolios and the associated pricing of new products. Our findings are consistent with related studies showing that payment policy can either encourage or discourage technology adoption (Dunn, Fernando and Liebman, 2023, 2024) and affect hospitals' capacity for capital investment (Yurukoglu, Liebman and Ridley, 2017). Our unified equilibrium framework advances this literature by allowing for the joint evaluation of diffusion rates, patient welfare, hospital profits, and insurer spending, answering the call for such integrated analysis by McClellan et al. (2017).

Fourth, we inform the literature on selective contracting in healthcare. Selective contracting is a widely studied cost-containment tool, with applications in prescription drug formularies (Duggan and Morton, 2010; Olssen and Demirer, 2024), provider networks (Sorensen, 2003; Pakes et al., 2015; Ho and Lee, 2019), and pharmacy benefit management (Starc and Swanson, 2021). The bulk of this research centers on the trade-off between the lower prices achieved through bargaining and the potential welfare losses from restricted patient access. We offer a new perspective by analyzing selective contracting through the lens of innovation diffusion. We demonstrate how this policy tool can be used not just to contain costs, but to actively steer technology adoption and strategically redistribute surplus among patients, providers, and manufacturers, creating the potential for "quadruple-win" outcomes.

Fifth, we contribute to the growing attention to demand-side policies that target healthcare inequity. High out-of-pocket costs for advanced medical devices, such as DES, often create significant barriers to accessibility, particularly for financially vulnerable patients. While the industrial organization literature often scrutinizes such subsidies through the lens of strategic insurer gaming (Decarolis, 2015) or complex market design interactions (Tebaldi, 2025), health policy research emphasizes their critical role in ensuring equity. A prominent example is the Affordable Care Act (ACA), which utilizes income-based Premium Tax Credits and Cost-Sharing Reductions to decouple access from ability to pay. Research consistently demonstrates that these means-tested mechanisms are effective at reducing out-of-pocket burdens and closing socioeconomic gaps in utilization (Myerson et al., 2021; Zheng et al., 2024). The relevance of such instruments is underscored by the policy debate surrounding the 2026 expiration of "enhanced" ACA subsidies, with projections indicating that the removal of these protections could reverse coverage gains for millions (Aboulafia, Gruber and Sommers, 2025). Using targeted patient coupons as an example, we demonstrate how hospitals may respond strategically in DES price and product offerings. Our simulation highlights the tradeoff between closing the DES usage gap, increasing government spending, and generating unintended consequences for unsubsidized patients.

Finally, our work contributes to the specific economics of the cardiac stent market. Prior research in this area has provided valuable insights into the upstream segment of the supply chain, including hospital–manufacturer price negotiations (Grennan, 2013, 2014; Grennan and Swanson, 2020) and the role of marketing and lobbying in procurement decisions (Bergman, Grennan and Swanson, 2021, 2022). We complement this body of work by focusing on the downstream market where patients and hospitals interact. In doing so, we illuminate how hospitals' strategic portfolio and pricing decisions ultimately mediate the process by which upstream innovations reach patients and determine the prices they face.

The rest of the paper is organized as follows. Section 2 describes the background and summarizes the data in our analysis sample. Section 3 lays out our structural model of patient choice of hospital and stent type on the demand side and hospitals' pricing and portfolio management decisions on the supply side. Section 4 presents our estimates, and Section 5 conducts three counterfactual simulations to highlight the interplay of market competition, patient willingness to pay for newness, and government reimbursements for DES. A brief conclusion is offered in Section 6.

2 Data and Institutional Background

We begin by outlining the key institutional features of the cardiac stent market in Taiwan, from the underlying clinical trade-offs between stent technologies to the specific reimbursement policies that shape the economic incentives of patients and hospitals. We then describe the unique datasets we assemble to analyze behavior within this setting.

2.1 Institutional Setting: Stent Implantation in Taiwan

The treatment of coronary artery disease encompasses a spectrum of options, ranging from non-invasive medication to open-heart surgery. Between these extremes, percutaneous coronary intervention (PCI) with stent implantation has become a standard, less invasive procedure. The intervention involves inserting a stent—a small, expandable mesh tube—to scaffold a narrowed artery and restore blood flow. The first wave of these devices, bare-metal stents (BMS), were effective scaffolds but were limited by high rates of in-stent restenosis, a re-narrowing of the artery caused by tissue regrowth (Agostoni et al. (2005)) .

To address this limitation, drug-eluting stents (DES) were developed. These devices are coated with antiproliferative drugs that significantly reduce the risk of restenosis. This clinical benefit, however, comes with significant economic and medical trade-offs. The drug coating can delay arterial healing, which in early-generation models was associated with a higher risk of stent thrombosis (blood clot formation) that happened in 20-30% of patients, particularly for older patients or those with severe comorbidities. Consequently, DES require a longer course of dual antiplatelet therapy (DAPT) to mitigate this risk (Tu et al. (2007). Kaiser et al. (2010).

Even within drug-eluting stents (DES), notable advancements over time have significantly improved clinical safety and efficacy—an evolution central to the technological "newness" incorporated into our demand model. The initial iteration of DES used strong polymers (like paclitaxel) to stop scar tissue from forming, but the thick coating irritated the artery, slowed healing, and slightly increased the risk of dangerous blood clots. Later iterations of DES improved on this by using thinner, stronger metals (like cobalt-chromium) and more natural, body-friendly drug coatings (like zotarolimus), giving the same benefits with much lower risks (Navarese et al. (2014), Bangalore et al. (2018), Kandzari et al. (2017)).

The healthcare environment in which these clinical decisions are made is defined by Taiwan's National Health Insurance (NHI) program.[2] During our study period, the NHI employed a "top-up" reimbursement model for stents: hospitals received a fixed base payment for any stent procedure, set at a level sufficient to cover the wholesale cost of a BMS. This structure created a powerful set of incentives. For patients, it meant that BMS were effectively free at the point of care, while the choice of a more advanced DES required a substantial out-of-pocket payment equal to the hospital's posted retail price net of the fixed NHI reimbursement. For hospitals, it created a margin management problem: their profit from a DES procedure depended on the wholesale price negotiated with manufacturers, the retail price set for patients, and the fixed NHI payment.

This system was subject to two system-wide reimbursement cuts during our sample period: a 26% reduction from 27,000 to 19,940 NTD (approximately $1 USD for 30 NTD) in 2009 and a further 18% reduction in 2012. These centrally mandated cuts directly compressed hospital

[2]Beyond NHI coverage, Taiwanese residents may also purchase private health insurance to offset out-of-pocket spending. However, despite its broad availability, private insurance is largely supplemental and typically offers limited reimbursement. As shown below, we observe price-elastic demand for DES across nearly all demographic groups, indicating that patients remain price-sensitive even when private insurance can partially defray the patient's out-of-pocket costs after NHI benefits are applied.

revenue per stent usage, providing exogenous variation that aids in the identification of supply-side responses. The combination of a fixed base payment and a patient-borne top-up cost makes patients highly sensitive to the posted price, rendering it a central strategic variable for hospitals competing for demand.

Finally, in contrast to the U.S. healthcare system, most physicians in Taiwan—including cardiologists performing stent implantation—are employed by hospitals. Because detailed information on hospital compensation structures and physician–patient interactions is unavailable, it is not feasible to model individual physician selection or the agency relationship between physicians and patients. Accordingly, throughout the paper we abstract from the role of individual physicians in hospital pricing and portfolio management. We further assume that patients select the optimal combination of hospital and stent type to maximize their utility. Although physicians may influence the final stent choice, several factors suggest that patients play a substantial role in this decision. Stent implantation is typically an elective procedure; the cost of the procedure itself (except for the out-of-pocket payment required for DES) is fully covered by the NHI regardless of hospital choice; and patients can compare out-of-pocket expenses across hospitals and DES models through the NHI's website. Together, these conditions foster an environment conducive to price-sensitive selection of both hospital and stent type.

2.2 Data Sources and Sample Construction

Our study population is defined as all patients receiving any stent treatment in the competitive Taipei metropolitan area, which includes Taipei City, New Taipei City, Keelung City and Yilan County, from 2007 to 2013. We rely on three comprehensive datasets.

First, we use individual-level inpatient claims from Taiwan's National Health Insurance (NHI). These administrative records contain detailed information on patient demographics, diagnoses (including the Charlson Comorbidity Index), and the specific stent model implanted. The presence of unique patient and hospital identifiers allows us to construct a complete treatment history for every patient at each hospital in our sample.

Second, because NHI claims do not capture the out-of-pocket payments that are central to the patient's choice problem, we supplement the claims data with a manually collected panel of hospital-specific DES prices. These data are compiled from public reports on the NHI website. By imputing these prices for every cardiac stent across all hospitals and quarters, we construct a hospital-model-time panel of the exact prices faced by patients, which we successfully match to approximately 90% of the DES procedures in our claims data.[3]

[3]We imputed cardiac stent prices using NHI-reported data through several steps. First, we obtained DES prices by type and brand directly from the NHI, covering 44 models across 102 hospitals between December 2006 and November 2013, with an average of 126 reports per hospital. To address missing observations, we calculated quarterly average prices for each hospital–model combination. Gaps between reports were filled under the assumption that hospitals maintained the same price between consecutive submissions. In cases where hospitals delayed reporting, we assumed their initial reported price applied up to four quarters prior to the first submission. This constructed price series matched 89.99% of DES usage records in the NHI claims data. Further details are provided in the appendix of Jin, Lien and Tao (2025).

Third, to properly account for socioeconomic heterogeneity, we augment the claims data with a measure of patient income. While NHI premiums are based on salary and can serve as an income proxy, a large portion of our sample consists of retirees. We therefore incorporate data from the Ministry of Finance that report the average annual taxable income per household at the level of a patient's township of residence. Our demand model uses it as a robust proxy for a patient's economic status to explain variations in both price sensitivity and technology preference.

A final crucial element of our data construction is the systematic tracking of innovation. We categorize each DES model by its manufacturer and, most importantly, by its generation. We define generation by timing to market *within* each manufacturer. We choose not to infer DES generation across manufacturers for two reasons. First, each manufacturer tends to improve the design of DES in its own pace and dimensions. Without clinical expertise, it is difficult to assess functional similarity across different brands. More importantly, a brand-specific definition of generation better matches how patients perceive "newness" in DES models, even when perceived novelty does not track objective technological advances or clinically meaningful improvements. As shown in Table 1, the major manufacturers in our sample introduced multiple DES generations over the study period. We consolidate near-simultaneous releases with similar technical specifications *within* the same brand[4] and group infrequently used brands into an "Other" category. These product-level data allow us to define a key variable in the demand model: a dummy of whether the focal DES model is the newest generation of its brand available anywhere in the market in the quarter of the stent surgery. It also allows us to define two key hospital actions in our supply-side model: an *adoption* (when a hospital first offers a brand) and an *upgrade* (when a hospital replaces an existing generation with a newer one of the same brand). For all analyses, we assume the basic BMS option is available in every hospital's portfolio in all periods.

As detailed in Jin, Lien and Tao (2025), only major and minor teaching hospitals are allowed to perform PTCA procedures and cardiac stent placements in Taiwan, but the volume of stent treatment (and subsequent financial implications) vary significantly among hospitals. We limit our analysis to hospitals that performed at least 75 PTCA cases and 50 stent cases annually in our sample period. This is to ensure that our analysis was not driven by hospitals that had few stent surgeries and thus may not engage in strategic pricing and portfolio management as other hospitals. In spite of this criterion, we still capture more than 98% of stent cases performed by hospitals in Taipei area, with 61,645 patient claim records across 20 hospitals in our final data sample (2007-2013).

2.3 Descriptive Evidence and Stylized Facts

The data reveal several key stylized facts about the Taipei DES market. First, the market is characterized by strong intergenerational substitution. Figure 1 shows that following the introduction

[4] A brand may simultaneously introduce multiple DES models that are made of the same materials but in different lengths because patients may demand different lengths depending on the size of the congested area in the blood vessel. Length alone is not a key dimension of DES innovation.

Table 1: List of Major Drug-Eluting Stent Models

Brand Name (Abbr.)	Gen	Initial Use	Stent Material	Coating Material	Length Choices	Diameter Choices	Note
Abbott (AB)	1	Oct 2008	L-605 CoCr Alloy	Everolimus and polymers	6	6	
	2	Nov 2008	L-605 CoCr Alloy	Everolimus and polymers	6	4	Consolidated with Gen 1
	3	Feb 2011	L-605 CoCr Alloy	Everolimus and polymers	8	5	
Medtronic (M4)	1	Mar 2007	Co alloy and PC coating	ABT-578	8	6	
	2	Jun 2008	Co alloy and PC coating	Zotarolimus	8	6	
	3	Jul 2009	Co alloy w/ BioLinx coating	Zotarolimus	8	6	
	4	Apr 2011	Co alloy w/ BioLinx coating	Zotarolimus	9	6	Rarely used, dropped
	5	Jan 2013	Co alloy w/ BioLinx coating	Zotarolimus	11	6	
Cordis (CD)	1	Nov 2006	316L stainless steel w/ Titanium Oxynitride	Sirolimus and polymers	6	8	
	2	Jul 2007	316L stainless steel	Sirolimus and polymers	6	5	
Boston Scientific (SB)	1	Nov 2006	316L stainless steel w/ polymers	Paclitaxel	7	8	Consolidated with Gen 2
	2	Oct 2006	316L stainless steel w/ Translute Polymer Carrier	Paclitaxel	7	5	
	3		316L stainless steel w/ Translute Polymer Carrier	Paclitaxel	8	8	Not observed in data
	4	Jan 2011	PtCr alloy w/ Translute Polymer Carrier	Paclitaxel	8	8	
	5	Nov 2010	PtCr alloy w/ PBMA-poly coating	PVDF-HFPpoly and Everolimus	8	6	Consolidated with Gen 4
Bio Sensor (BS)	1	Oct 2010	316L stainless steel	Biolimus w/ PLA	7	7	
	2	Feb 2012	316L stainless steel	Biolimus w/ PLA	8	6	

Notes: This table details the major DES models from five prominent manufacturers. Generations are consolidated if released nearly simultaneously with similar specifications (e.g., Abbott Gen 1 and 2). Some globally available models (e.g., Boston Scientific Gen 3) are omitted as they do not appear in our data. Less common brands are aggregated into an "Other" category for analysis and are not listed here.

of a new DES generation by a manufacturer, the market share of the prior generation typically declines sharply. This rapid substitution suggests a powerful latent demand for technological novelty from patients and physicians, which motivates the inclusion of a "newest-generation" attribute in our demand model. However, the speed and completeness of these transitions vary across brands, and newer generations do not always drive out older ones entirely, suggesting that the preference for newness interacts with brand loyalty, hospital pricing, and other market frictions.




Figure 1: DES Quantity of Different Generations by Brand

Second, pricing patterns reflect both frontier competition and adjustment frictions. As shown in Figure 2, the average patient-paid price for a given brand tends to track the price of its newest available generation, indicating that the locus of competition is at the technological frontier. At the same time, we observe substantial price dispersion across brands for clinically similar products. Even within the same product (by brand and generation), we observe some price dispersion across hospitals in the same hospital system, suggesting that patient-facing DES price is set by individual hospitals rather than the headquarter of the hospital system they belong to.[5] We also observe pricing anomalies, where older generations are sometimes priced higher than newer ones in the market. This is partly driven by selection, as earlier adopters of the new generation tend to be bigger hospitals that charged a lower price for the old generation, probably because they can

[5]For example, Chang Gung Hospital network, the largest hospital system in Taiwan, comprises seven major tertiary hospitals located in Linkou, Taipei, Taoyuan, Keelung, Yunlin, Chiayi, and Kaohsiung, along with additional affiliated or contract-operated institutions. Notably, despite belonging to the same hospital network, both the prices of coronary stents and the range of stent products available vary across individual hospitals, reflecting differences in procurement decisions and clinical preferences.

negotiate for a lower wholesale cost from the manufacturer. This evidence points to significant brand differentiation and, more importantly, frictions in hospitals' portfolio and pricing adjustments, motivating a supply-side model where such adjustments are costly.





Figure 2: Average Price Across Generations



(a) Adoption Delay

(b) Upgrade Delay

Figure 3: Distribution of Adoption and Upgrade Delays (in quarters)

Third, the timing of technology adoption and upgrading demonstrates some heterogeneity across hospitals. Figure 3 plots the distribution of delays, measured in quarters from a new product's market introduction to its appearance in a hospital's portfolio, conditional on the hospitals that eventually include the product in their portfolio. While the observed dispersion in delay suggests

some market friction, most adoption and upgrading events occur relatively quickly, typically within one to three quarters of a new product's market availability, which limits the salience of long-term strategic waiting. This heterogeneity is a central feature of the diffusion process and calls for hospital-specific fixed costs of portfolio adjustment, a key component of our supply-side model.

Finally, summary statistics confirm the powerful role of patient price sensitivity. As shown in Table 2, despite the clinical advantages of DES, the free BMS option consistently retains more than 50% of the market in our sample period (2007-2013). The out-of-pocket prices for DES are substantial, averaging 52,000–65,000 NTD, a figure comparable to the average monthly wage in Taiwan during this period and almost three times the average reimbursement rate from the NHI. This underscores the salience of the patient's cost-sharing burden and motivates our focus on out-of-pocket price as a primary determinant of demand.

Table 2: Summary Statistics on Patients' Stent Usage and Choices

	Mean	Std. Dev.	Min	Max
Number of patients per hospital-quarter	108.15	92.29	1	377
Patients using DES	52.56	62.94	1	279
Patients using BMS	56.74	39.90	1	251
Number of hospital-brand choices	90.18	19.19	41	114
Number of brand choices within hospital	4.55	1.39	1	7
Patient-paid prices of DES (1,000 NTD)				
Abbott	56.90	7.66	30.66	78.75
Bio Sensor	55.40	7.44	44.36	68.22
Cordis	65.69	3.90	43.31	74.56
Medtronic	57.40	5.95	29.71	67.96
Boston Scientific	52.45	9.52	26.09	72.00
Other	52.22	6.08	32.92	70.05
Percentage of patients using DES (patient-level average)	48.09%	49.96%	0%	100%

Taken together, these patterns—rapid but incomplete intergenerational substitution, pricing that reflects both frontier competition and adjustment frictions, heterogeneous adoption timing, and persistent price sensitivity—illustrate a market shaped by a complex interplay of forces. A structural model is therefore necessary to disentangle these mechanisms and to quantify their impact on hospital strategy, patient welfare, and the diffusion of innovation.

3 Model

To formally analyze the diffusion of drug-eluting stents (DES), we develop and estimate a structural model of the Taipei metropolitan market. The model is designed to capture the equilibrium interactions among three types of agents: (i) upstream manufacturers, who periodically introduce new DES generations; (ii) downstream hospitals, which strategically manage their DES portfolios

and set prices; and (iii) patients, who choose a hospital and a stent for treatment.

Given that all five major stent manufacturers in our sample period are foreign to Taiwan (four are based in the US and one is headquartered in Singapore), their R&D decisions are made in a global context, and the Taiwanese market is relatively small, we treat the arrival of new DES generations as an exogenous process. Our analysis therefore focuses on the downstream market equilibrium. We do not model physicians as separate strategic agents, because they are salaried hospital employees in Taiwan, which aligns their primary incentives with those of the hospitals. The model therefore centers on the two key strategic actors in the downstream market—patients and hospitals—whose interactions are formulated as a sequential game.

3.1 Patients' Demand

On the demand side, we specify a discrete-choice model of a patient's joint selection of a hospital and a stent. Let i index patients, h hospitals, m stent brands, and t quarters. The choice set for a patient in quarter t consists of all hospitals in Taipei ($h \in H$) and the specific stent portfolios, M_{ht}, that they offer. The observable characteristics of each available stent $m \in M_{ht}$ include its patient-paid price, p_{hmt}, its generation, g_{hmt}, and an indicator for whether it is a DES ($isDES_m = 1$) or a BMS ($isDES_m = 0$).[6] To capture the value of innovation highlighted in our stylized facts, we define a variable New_{hmt}, which equals one if stent m is the newest generation of its brand available anywhere in the market in quarter t.[7] The cost of access is measured by dis_{ih}, the straight-line distance between the centroid of the patient's township of residence and the hospital's location.

We model this choice under an assumption of full information. This is justified by two key institutional features: first, the NHI publicly discloses the prices of all DES models at every hospital, and second, Taiwanese media frequently report on these price differences, reinforcing patient awareness. While we formally model the patient as the decision-maker, we interpret the observed choice as the outcome of a joint decision process between the patient and their physician. Consistent with NHI policy, we assume every hospital offers a BMS ($m = 0$) in every period at zero out-of-pocket cost to the patient ($p_{h0t} = 0$), and we normalize its "newness" attribute to zero ($New_{h0t} = 0$).

Patient i's indirect utility from choosing stent brand m at hospital h in quarter t is specified as:

$$u_{ihmt} = \beta_{1i} isDES_m + \beta_{2i} New_{hmt} + \beta_{3i} dis_{ih} + \beta_{4i} (isDES_m \times dis_{ih}) + \beta_{5i} p_{hmt} + \xi_{hmt} + \varepsilon_{ihmt} \equiv \delta_{ihmt} + \varepsilon_{ihmt}, \tag{1}$$

where δ_{ihmt} represents the mean utility component. The preference parameters β_{ki} are patient-specific, allowing for heterogeneity in tastes for DES status (β_{1i}), newest-generation technology (β_{2i}), travel distance (β_{3i}), the interaction between DES status and distance (β_{4i}), and price (β_{5i}). The term ξ_{hmt} captures unobserved quality attributes of a hospital-brand combination, part of

[6] We denote the BMS option as m=0 without distinguishing between different BMS brands. However, BMS offered by different hospitals is treated as distinct treatment options.

[7] The definition of New is brand-relative for two reasons. First, we lack sufficient information and domain expertise to establish comparable generations across brands. Second, this brand-specific framing aligns with how patients perceive "newness" in the market. Importantly, newness reflects perceived novelty rather than an objective measure of technological improvement or meaningful functional differences.

which can be decomposed into hospital and manufacturer fixed effects (ξ_h and ξ_m). The idiosyncratic error term, ε_{ihmt}, is assumed to follow a Type I extreme value distribution. The mean utility from the BMS option ($m = 0$) at hospital h is normalized to the hospital fixed effect, $\delta_{ih0t} = \xi_h$.

To capture rich, observable sources of preference heterogeneity, we allow the random coefficients to vary with patient characteristics:

$$\beta_{ki} = \beta_{k0} + \beta_{k1} charlson_i + \beta_{k2} income_i + \beta_{k3} male_i + \beta_{k4} age_i + v_{ki}, \quad \text{for } k = 1, \ldots, 5.$$

These characteristics include the patient's health status (Charlson Comorbidity Index), the average taxable income of their township of residence, their gender, and their age. The vector $\mathbf{v}_i = (v_{1i}, \ldots, v_{5i})$ represents unobserved individual-specific taste shocks, which are assumed to follow a distribution $G(\cdot)$. Given this mixed logit specification, the probability that patient i chooses stent brand m at hospital h is:

$$s_{ihmt}(\mathcal{P}_t, \mathcal{M}_t) = \frac{\exp(\delta_{ihmt})}{\sum_{h' \in H} \sum_{m' \in M_{h't}} \exp(\delta_{ih'm't})}, \tag{2}$$

where the denominator sums over all available hospital-brand combinations in the market. The market share for each product is then obtained by integrating these individual choice probabilities over the joint distribution of observed demographics and unobserved preference shocks:

$$s_{hmt}(\mathcal{P}_t, \mathcal{M}_t) = \iint s_{ihmt} \, dF(Income_i, Charlson_i, male_i, age_i) \, dG(\mathbf{v}_i). \tag{3}$$

Price Endogeneity and Instrumental Variables. A primary concern in this specification is that posted prices, p_{hmt}, may be endogenous if they are correlated with unobserved product quality captured in the error term, ξ_{hmt}, even after we control for hospital and manufacturer fixed effects (ξ_h and ξ_m). We address this using a control-function approach. We specify a set of instrumental variables that are correlated with hospital costs but are plausibly orthogonal to unobserved demand shocks. These instruments include: (i) quarterly average exchange rates (NTD/USD and NTD/SGD), which affect the import costs of stents; (ii) historical adoption patterns, such as the number of other hospitals that adopted the same brand prior to the current period, which may proxy for learning or scale effects in procurement; and (iii) measures of historical peer adoption of the latest generation, which capture competitive cost pressures. The control function includes the residual from a first-stage regression of price on these instruments and other exogenous covariates. This residual is then included as an additional regressor in the utility function to purge the endogeneity bias. We carry this residual forward into all subsequent demand computations, supply-side estimation, and counterfactual analyses; for any new hospital-brand-time combinations that arise in counterfactuals, we set the residual to zero. This procedure ensures that price endogeneity is controlled for consistently throughout the analysis.

3.2 Supply Model

The supply side of the market is characterized by the strategic behavior of hospitals, which compete by adjusting their DES portfolios and setting prices on a quarterly basis. We model this interaction as a sequential game, which allows us to distinguish between hospitals' long-run investment decisions and their short-run pricing conduct. The game unfolds in three stages:

- **Stage 1 (Portfolio Adjustment)**: Hospitals simultaneously choose their technology portfolios. Each hospital can decide to: (i) adopt a new DES brand not previously offered, (ii) upgrade an existing brand to its latest generation, or (iii) maintain its current portfolio. This is the primary investment decision.
- **Stage 2 (Pricing Competition)**: After observing the portfolio choices of all rivals, hospitals simultaneously set patient-paid prices for all DES models they offer.
- **Stage 3 (Patient Choice)**: Patients observe the available portfolios and prices across all hospitals and make their treatment choices, as described in the demand model.

The model is solved via backward induction, beginning with the pricing stage.

Stage 2: Hospitals' Pricing Decisions

In the second stage, given a fixed configuration of hospital portfolios across the market, $\mathcal{M}_t = \{M_{ht}\}$, each hospital sets prices for the DES models in its portfolio to maximize its current-period variable profit. We assume that hospitals engage in Bertrand-Nash pricing competition. The profit function for hospital h is:

$$\pi_h(M_{ht}, \mathcal{M}_t) = \max_{\{p_{hmt}\}_{m \in M_{ht}}} \left\{ \sum_{m \in M_{ht}, m \neq 0} (p_{hmt} + r_t - c_{hmt})\, s_{hmt}(\mathcal{P}_t, \mathcal{M}_t) + 0.2 r_t s_{h0t}(\mathcal{P}_t, \mathcal{M}_t) \right\}, \tag{4}$$

where s_{hmt} is the market share of product m at hospital h, r_t is the fixed NHI reimbursement for a stent procedure, and c_{hmt} is the hospital's marginal cost for DES model m. During our sample period, the NHI lowered r_t twice, which we incorporate as raw data. The term $(p_{hmt} + r_t)$ represents the total revenue per DES procedure. For the BMS option ($m = 0$), which is free to patients, we assume hospitals earn a 20% margin on the reimbursement payment, consistent with NHI regulations for medical devices and drugs.[8]. The first-order conditions from this pricing problem define a system of equations for all hospitals. By inverting this system, we can recover the implied marginal cost for each DES model offered in the market:

$$\mathbf{c}_t = \mathbf{r}_t + \mathbf{p}_t + (\Delta_{-0t})^{-1} (0.2 \mathbf{r}_t \Delta_{0t} + \mathbf{s}_t), \tag{5}$$

[8]Under this policy, reimbursement is based on the average input cost across hospitals, with an additional 20% allocated as hospital profit.

where Δ_{-0t} is the matrix of own- and cross-price derivatives of DES shares with respect to DES prices, and Δ_{0t} is the vector of derivatives of BMS shares with respect to DES prices. These recovered marginal costs are crucial inputs for the subsequent analysis, as they allow us to compute the expected profits that drive hospitals' portfolio decisions in the first stage.

Stage 1: Hospitals' Portfolio Adjustment Decisions

In the first stage of the game, each hospital chooses its technology portfolio to maximize its total expected payoff. Based on our empirical observation that hospitals rarely make more than one portfolio change in a given quarter, we simplify the choice set: a hospital can make at most one adjustment per period, either adopting one new brand, upgrading one existing brand, or making no change. The value to hospital h of choosing a new portfolio M'_{ht}, given its current portfolio M_{ht} and the choices of its rivals $\mathcal{M}'_t$, is:

$$V_{ht}(M'_{ht}, M_{ht}, \mathcal{M}'_t) = \pi_h(M'_{ht}, \mathcal{M}'_t) - c^M_{ht}(M_{ht}, M'_{ht}) + v_{ht}, \tag{6}$$

where $\pi_h(\cdot)$ is the expected variable profit from the second-stage pricing equilibrium, $c^M_{ht}(\cdot)$ is the one-time, fixed cost of the portfolio change (either an adoption or an upgrade), and v_{ht} is an i.i.d. Type I extreme value shock private to the hospital.

Although portfolio decisions are inherently dynamic, we model this stage as a static game in which hospitals maximize current-period profits net of adjustment costs. This simplification is motivated by three considerations. First, as our descriptive evidence shows, most adoption and upgrading events occur relatively quickly, typically within one to three quarters of a new product's market availability, which limits the salience of long-term strategic waiting. Second, the set of competing hospitals in our sample is stable, mitigating concerns about strategic portfolio choice aimed at deterring entry. Third, a fully dynamic model with this many products and firms would be computationally infeasible, as the state space of all possible portfolio combinations is immense.[9] Our static approach is consistent with recent work analyzing complex product-portfolio problems, such as Wollmann (2018) and Olssen and Demirer (2024).

The probability that hospital h chooses portfolio M'_{ht} follows a standard logit form, which we use as the basis for a maximum likelihood estimator of the parameters of the adoption and upgrade cost functions.

$$Pr_t(M'_{ht}|M_{ht}, \mathcal{M}_t) = \frac{\exp\left(V_{ht}(M'_{ht}, M_{ht}, \mathcal{M}_t)\right)}{\sum_{M' \in \mathcal{A}_{ht} \cup \{M_{ht}\}} \exp\left(V_{ht}(M', M_{ht}, \mathcal{M}_t)\right)}, \tag{7}$$

where $\mathcal{A}_{ht}$ is the set of all feasible single portfolio adjustments (adoptions or upgrades) for hospital h at time t.

[9] For example, if each of the 20 hospitals can choose whether or not to carry each of the 5 major DES brands, there are $(2^5)^{20}$ possible portfolio states, even before accounting for generations.

4 Estimation Results

We begin with demand-side estimates, which reveal rich patterns of patient heterogeneity and provide crucial insights into how preferences for innovation and price sensitivity shape market outcomes. We then turn to the supply side, showing how hospitals' strategic decisions regarding technology adoption and pricing respond to demand patterns and competitive pressures.

4.1 Demand Estimation

We estimate the demand model using detailed, individual-level data on patient treatment choices. For each patient in a given quarter, the choice set encompasses all available DES and BMS options across every hospital in the Taipei area. Specified as a mixed logit, the model allows for rich, unobserved heterogeneity in patient preferences alongside heterogeneity based on observable patient characteristics. We estimate the model via simulated maximum likelihood. Acknowledging that out-of-pocket prices can be endogenous due to unobserved product-hospital quality attributes, we employ a control-function approach using the instrumental variables detailed in Section 3.

Table 3 presents the estimation results, moving from a standard conditional logit (Column 1) to our preferred mixed logit specification with a full set of interactions (Column 4). The superior fit and refined insights from the latter specification confirm the necessity of modeling both observed and unobserved heterogeneity, which forms the basis for our discussion.

The estimation results for our preferred specification reveal two primary determinants of patient choice. First, patients are sensitive to out-of-pocket costs, as indicated by the negative and statistically significant mean price coefficient. This price sensitivity represents a significant friction in the adoption of new technologies. Second, patients exhibit a strong preference for clinical novelty, evidenced by the large, positive, and significant coefficient on "newest-generation". This preference for new technology creates a demand-side incentive for hospitals to update their stent portfolios.

The model further reveals substantial heterogeneity in patient preferences. The estimated interaction terms show that price sensitivity is significantly attenuated for higher-income patients but is more pronounced for patients with a higher Charlson Index. This suggests that the cost of new technology is a more significant consideration for lower-income and sicker patients. The preference for DES technology over BMS also varies, increasing with patient income and age. This observed heterogeneity indicates that different patient segments evaluate the trade-off between price and technology differently.

Finally, additional estimates support the validity of our model specification. The coefficient on the control-function residual is positive and highly significant, confirming the presence of price endogeneity and the necessity of our instrumental variable strategy. The coefficient on travel distance is negative and significant, consistent with geographic competition. The disutility from travel is larger for sicker and richer patients, likely reflecting higher opportunity costs. These ancillary results are consistent with economic theory and support the robustness of our main findings.

Implications for Innovation Diffusion. The demand estimates reveal two key insights for

Table 3: Demand Estimation Results

Variable	(1) Clogit 1	(2) Clogit 2	(3) Mixlogit 1	(4) Mixlogit 2
Price Effects				
Price	-0.009***(0.001)	-0.026***(0.004)	-0.036***(0.002)	-0.025***(0.005)
Price × Charlson		-0.004***(0.001)		-0.004***(0.001)
Price × Income		0.005***(0.002)		0.004*(0.002)
Price × Male		-0.004***(0.001)		-0.004**(0.002)
Price × Age		-0.001***(0.000)		-0.001***(0.000)
Newest Generation Effects				
Newest Generation	0.318***	0.659***(0.142)	0.470***(0.021)	0.636***(0.143)
Newest Gen × Charlson		-0.027(0.026)		-0.029(0.026)
Newest Gen × Income		-0.188***(0.061)		-0.175***(0.063)
Newest Gen × Male		0.038(0.050)		0.040(0.050)
Newest Gen × Age		-0.000(0.002)		0.001(0.002)
Distance Effects				
Distance	-0.072***(0.000)	-0.061***(0.005)	-0.105***(0.001)	-0.088***(0.005)
Distance × Charlson		-0.006***(0.001)		-0.007***(0.001)
Distance × Income		-0.026***(0.003)		-0.012***(0.003)
Distance × Male		-0.002(0.001)		-0.002(0.002)
Distance × Age		-0.000(0.000)		0.000(0.000)

Variable	(1) Clogit 1	(2) Clogit 2	(3) Mixlogit 1	(4) Mixlogit 2
DES Indicator Effects				
DES Indicator	-1.163***(0.056)	-0.232(0.262)	0.620***(0.097)	-0.297(0.295)
DES × Charlson		-0.106**(0.043)		-0.109**(0.049)
DES × Income		0.462***(0.108)		0.538***(0.125)
DES × Male		0.097(0.086)		0.090(0.097)
DES × Age		0.057**(0.003)		0.057*(0.003)
DES Interaction with Distance				
DES × Distance	0.002***(0.000)	-0.003**(0.001)	0.001***(0.000)	-0.004***(0.001)
DES × Dist × Charlson		0.000*(0.000)		0.000*(0.000)
DES × Dist × Income		0.005***(0.001)		0.006***(0.001)
DES × Dist × Male		0.001***(0.000)		0.001***(0.000)
DES × Dist × Age		0.000(0.000)		0.000(0.000)
Control Function				
Control Function Residual	0.010***(0.020)	0.037***(0.002)	0.037***(0.002)	0.037***(0.002)
Standard Deviations of Random Coefficients				
SD Price			-0.000(0.002)	-0.000(0.002)
SD DES Indicator			0.100(0.148)	0.124(0.171)
SD Newest Generation			-0.141(0.142)	-0.160(0.147)
SD Distance			0.073***(0.001)	0.072***(0.001)
Hospital FE	Yes	Yes	Yes	Yes
Manufacturer FE	Yes	Yes	Yes	Yes
N	5579861	5579861	5579861	5579861
Log-likelihood	-2.45e+05	-2.28e+05	-2.29e+05	-2.28e+05

Standard errors in parentheses. * $p < 0.1$, ** $p < 0.05$, *** $p < 0.01$

innovation diffusion. First, the substantial price sensitivity (with own-price elasticities generally ranging from -3 to -1, see Appendix C for details) means that high out-of-pocket costs can significantly limit adoption of new technologies, even when patients value innovation. Second, the strong preference for newest-generation stents creates powerful incentives for hospitals to invest in technology upgrades, but the distribution of these preferences across patient types suggests that the benefits of innovation may not be equally accessible to all patients. To quantify the value patients place on innovation, we calculate their willingness to pay (WTP) and willingness to travel (WTT) for newest-generation stents. For an average patient, these are substantial, at approximately 5,690 NTD and 5.03 kilometers, respectively (see Appendix B for calculation details). These values underscore the powerful market incentives for hospitals to invest in the latest technologies.

4.2 Supply Estimation

Supply-side estimation proceeds in two steps. First, we recover hospital–brand–quarter marginal costs by inverting the Bertrand–Nash first-order conditions using demand estimates. Second, we estimate fixed costs of portfolio adjustment—adoption of new brands and upgrades of existing lines—using a discrete-choice framework fit to observed portfolio changes. These primitives discipline the counterfactuals on pricing and diffusion.

This two-step approach is standard in empirical IO studies of differentiated products. The inversion step uses the estimated demand elasticities to map observed prices and shares into implied marginal costs under the assumed pricing game, thereby separating preference-driven demand variation from cost-driven supply behavior. The second step models portfolio modification as adjustment over time along the extensive margin. While we do not fully solve a dynamic program, the discrete-choice specification captures state dependence via observed portfolio composition and fixed effects and provides a tractable representation of adjustment costs that is sufficient for the counterfactual exercises below.

Recovering Marginal Costs. Using the demand estimates from Column (4) of Table 3, we recover marginal costs by inverting the first-order conditions from hospitals' pricing decisions. Under Bertrand–Nash competition, these conditions imply

$$\mathbf{c}_t = \mathbf{r}_t + \mathbf{p}_t + (\Delta_{-0t})^{-1}\Big(0.2\,\mathbf{r}_t\,\Delta_{0t} + \mathbf{s}_t\Big),$$

where $\mathbf{p}_t$ stacks hospital–brand DES prices, $\mathbf{r}_t$ is the reimbursement vector, and $\mathbf{s}_t$ denotes DES market shares. The matrix Δ_{-0t} contains own- and cross-price derivatives of DES shares with respect to DES prices, while Δ_{0t} collects the derivatives of BMS shares with respect to DES prices, both evaluated at observed prices and demand parameters. We compute these derivatives from demand estimates using simulation draws and the control-function residuals retained from demand.

Operationally, we construct Δ_{-0t} and Δ_{0t} at the hospital–brand level each quarter, invert Δ_{-0t} using a numerically stable routine with Tikhonov regularization for near-singular systems, and obtain implied marginal costs $\mathbf{c}_t$. We drop cells with predicted shares below 10^{-5} to avoid numerical

artifacts.[10] For hospital–brand–quarter combinations not observed in the data but required for counterfactuals, we impute marginal costs via a linear model with hospital, brand, and quarter fixed effects fit on the recovered $\mathbf{c}_t$.

Recovered costs indicate modest cross-manufacturer dispersion around 50,000 NTD per unit (Cordis highest at 58,000; "Other" lowest at 45,000). Costs decline from roughly 55,000 NTD in 2008 to 45,000 NTD in 2012, consistent with the 2009 reimbursement cut and intensified entry. Major teaching hospitals face lower marginal costs (48,000 NTD) than minor teaching hospitals (50,000 NTD), consistent with scale and bargaining power in procurement.

Adoption and Upgrade Cost Estimation. The second step of our supply-side estimation quantifies the fixed costs that hospitals incur when adjusting their DES portfolios. We model the hospital's decision to adopt a new brand or upgrade an existing one as a discrete choice, where the cost of each action is a function of hospital characteristics, current portfolio composition, and broader market conditions. Because it is rare to observe any hospital engaging in multiple adoption or upgrade actions in a quarter, we limit at most one action when a hospital adjusts its DES portfolio in a quarter. The action options available to a hospital-quarter depends on the brand-generation available in the market, and the hospital's existing portfolio. The model includes an unobserved cost component assumed to follow a Type I extreme value distribution.

We estimate the structural parameters of the cost function via maximum likelihood, using the observed sequence of hospital portfolio choices. This approach allows for a flexible specification that includes a rich set of fixed effects to control for unobserved, time-invariant heterogeneity at the brand, year, and hospital levels. As a robustness check on the importance of these controls, we evaluated a sequence of specifications: a model with only the 11 core covariates yields a log-likelihood of -228.643; successively adding brand, year, and finally hospital fixed effects improves the fit to -215, -195, and -170, respectively. The material gains at each step confirm that unobserved heterogeneity is a key feature of the data and that its inclusion is critical for obtaining reliable cost estimates. While alternative estimation approaches for portfolio-adjustment models exist, such as moment-inequality estimators, they are computationally infeasible in our setting. With 73 parameters in our full specification, evaluating the necessary inequality conditions would require exploring a parameter space of intractable dimensionality (e.g., 10^{73} combinations for a coarse 10-point grid search). Our MLE approach is therefore the most viable strategy that accommodates the institutional richness of the market.

Table 4 reports the parameter estimates from our preferred specification with a full set of fixed effects. The results indicate the presence of both economies and diseconomies of scope. The negative and significant coefficient on portfolio size in both the adoption and upgrade cost functions (-9.371 and -2.627, respectively) implies substantial economies of scope: hospitals with larger existing portfolios face lower incremental costs for both adding new product lines and upgrading existing ones. In contrast, the positive and significant coefficient on the number of newest-generation stents already in the portfolio (4.492 for adoption; 2.575 for upgrade) points to diseconomies of scope as

[10] Results are insensitive to thresholds between 10^{-6} and 10^{-4}.

Table 4: Adoption and Upgrade Cost Estimates

	Specification 1		Specification 2	
Variable	Est.	Std. Err.	Est.	Std. Err.
Adoption Cost				
Portfolio size	-9.213	1.3269	-9.3706	1.3306
No. of hospitals using same brand/20			7.3858	5.8832
No. of hospitals using the latest same brand/20			-7.6596	4.1622
No. of latest generation within own portfolio	4.5766	1.1429	4.4923	1.0971
Upgrade Cost				
Portfolio size	-2.5913	0.6946	-2.6266	0.7244
No. of hospitals using same brand/20			4.4148	7.8712
No. of hospitals using the latest same brand/20			3.1591	2.4551
No. of latest generation within own portfolio	2.5763	0.4771	2.5751	0.4918
Duration of current generation			-0.0069	0.0732
Duration of newest gen since introduction			-0.8143	0.4963
Duration of newest gen since introduction, sq			0.0498	0.0302
Brand FE	Yes		Yes	
Year FE	Yes		Yes	
Hospital FE	Yes		Yes	
Likelihood	-174.843		-170.373	

a hospital's portfolio becomes more technologically advanced. To accommodate potential social learning between hospitals, we allow a hospital's fixed costs of adoption or upgrade to depend on the fraction of other hospitals using the same brand or the latest generation of the same brand up to the study quarter. None of these social learning variables turns out significant, confirming our understanding that social learning and other strategic dynamics between competing hospitals do not play an important role in hospitals' portfolio adjustment.

To translate these parameters into economically meaningful magnitudes, we compute the implied distribution of fixed costs. The median fixed cost for adopting a new brand is estimated to be 5.30 million NTD, with an interquartile range of 1.11 to 8.84 million NTD. The cost to upgrade an existing product line is considerably lower, with a median of 1.50 million NTD and an interquartile range of 0.59 to 2.89 million NTD. This significant cost differential provides a clear economic explanation for the empirical pattern wherein hospitals are more inclined to incrementally upgrade their existing technology portfolios than to adopt products from entirely new manufacturers. The magnitude of these costs underscores that portfolio adjustments represent significant strategic investments for hospitals.

Model Validation and Fit. To validate the supply-side model, we assess its ability to replicate key patterns of technology adoption and upgrading observed in the data. A well-fitting model should capture not only the cross-sectional distribution of portfolio adjustments across different product

lines but also the aggregate dynamics of diffusion over time.

We conduct two validation exercises by these criteria. First, we examine the model's cross-sectional fit by comparing the actual number of adoption and upgrade events for each manufacturer with the model-imputed counterparts. The imputed values are calculated by summing the model-predicted probabilities of each event across all hospitals and quarters. Table 5 presents this comparison. The model demonstrates a high degree of accuracy, closely matching the actual event counts for most major brands (e.g., Abbott, Bio Sensor, Medtronic). While minor deviations exist—such as a slight overprediction of adoptions for Cordis and a slight underprediction of upgrades for Boston Scientific—the overall correspondence confirms that the model successfully captures the salient features of cross-brand heterogeneity in portfolio adjustments.

Second, we assess the model's ability to reproduce the temporal patterns of diffusion. Figure 4 plots the actual and imputed time series for the total number of adoptions and upgrades per quarter. The figure shows that the model tracks the historical evolution of these events remarkably well, capturing both the timing and the intensity of portfolio adjustments over the sample period. The close alignment between the imputed and actual series provides strong evidence that the model's underlying parameters are well-identified and that it adequately represents the dynamic incentives facing hospitals.

Taken together, the results from these validation exercises indicate that the estimated model successfully replicates both the cross-sectional and time-series dimensions of hospital portfolio decisions. This provides confidence in the model's structural integrity and supports its use for conducting meaningful counterfactual policy simulations.

Table 5: Imputed vs. Actual Adoption and Upgrade Occurrences

	Abbott	Bio Sensor	Cordis	Medtronic	Other	Boston Sci.
Actual adoptions	19	15	3	17	15	0
Imputed adoptions	19	15	5	17	15	0
Actual upgrades	14	13	11	45	0	13
Imputed upgrades	14	13	10	36	0	9
Actual no-change	153	77	65	145	51	82
Imputed no-change	153	79	64	157	54	88

Note: Imputed statistics sum predicted probabilities across all hospitals for each DES brand. "No-change" refers to instances with no portfolio modification when at least one adjustment option was feasible.

The recovered marginal costs, summarized graphically in Figure 5, provide a final, detailed view of the underlying cost structure of the market. The distribution of costs by manufacturer (panel a) reveals a market average of approximately 50,000 NTD, with modest but systematic variation across firms. The temporal trend (panel c) shows a clear decline in average marginal costs for DES from approximately 55,000 NTD in 2008 to 45,000 NTD in 2012. This trend is consistent with the effects of increased competition from new entrants and a reimbursement policy change in 2009, both of which likely increased hospitals' bargaining power with upstream suppliers. Furthermore, the cost differential between major and minor teaching hospitals (panel d) confirms the presence




Figure 4: Imputed vs. Actual Frequency of Adoption and Upgrade Over Time

Note: "Imputed" is the sum of model-predicted probabilities of hospitals' adoptions and upgrades in each quarter; "Actual" is the observed count.




Figure 5: Summary of Recovered Marginal Costs

of scale or bargaining advantages, providing a direct economic rationale for the observation that larger institutions are often the earliest adopters of new technologies.

Collectively, the demand and supply-side estimates illuminate the central economic forces that jointly shape market outcomes in this industry. On the demand side, a strong patient preference for technological novelty creates a significant commercial incentive for hospitals to offer the latest prod-

ucts. However, this is counterbalanced by substantial price sensitivity, which acts as a considerable barrier to access, particularly for lower-income and clinically more vulnerable patients.

These findings set the stage for our counterfactual analysis. The tension between patient demand for innovation and the price sensitivity that limits access, combined with the strategic investment decisions of hospitals facing significant adoption costs, raises important questions about market performance and policy design. The next section uses our estimated structural model to evaluate how alternative market structures and reimbursement policy interventions could better align private incentives with social welfare in the context of medical technology diffusion.

5 Counterfactual Simulations

The continuous introduction of new DES models by upstream manufacturers presents a fundamental economic challenge: can market mechanisms provide sufficient incentives for downstream adoption while maintaining affordable patient access? To answer this question, our counterfactual simulations leverage the structural estimates to decompose the diffusion process and quantify welfare implications. This analysis reveals how the interaction between market structure and policy design determines both the pace of technological progress and its distributional consequences.

We proceed in two complementary dimensions. First, we examine how varying degrees of market concentration interact with heterogeneous patient preferences for innovation to shape equilibrium outcomes, revealing a fundamental tension between competitive pricing and investment incentives. Second, we evaluate alternative reimbursement mechanisms, ranging from simple reimbursement rate change to supply-side selective contracting and demand-side patient subsidies. When we quantify their differential impacts, we also highlight how the efficacy of these policies vary by market structure.

5.1 Market Competition and Patient Demand

The canonical industrial organization question regarding the competition-innovation nexus (Aghion et al., 2005) takes on a distinct character in markets where innovation diffusion operates through intermediaries. In our setting, hospitals function as gatekeepers whose portfolio choices determine both the availability and pricing of new technologies. This intermediation creates a fundamental tension: while competition enhances patient access through lower prices and expanded aggregate choice, it simultaneously erodes the quasi-rents that incentivize individual hospitals to adopt costly innovations. Furthermore, the transmission of patient preferences into market outcomes is not uniform; as we show, market structure mediates how demand shocks are distributed, determining whether changes in valuation are passed through to consumers or captured by intermediaries.

Market Structure and Equilibrium Outcomes. To quantify the relationship between market concentration and technology diffusion, we simulate equilibria under alternative competitive environments. We consider three scenarios: a highly concentrated duopoly ($N = 2$), an intermediate case with moderate competition ($N = 10$), and the baseline competitive market observed in our

data ($N = 20$). For scenarios with reduced hospital counts, we randomly select N hospitals from our sample and compute equilibria using the iterative best-response algorithm detailed in Appendix A. Results represent averages across ten independent draws to ensure robustness.[11]

Table 6: Counterfactual 1: Market Competition Effects on DES Market Outcomes

Measure	**N=2**	**N=10**	**N=20**
Panel A: Quarterly Market Outcomes			
Consumer surplus (million NTD)	60.81	138.00	175.84
Average patient-paid DES price (thousand NTD)	70.13	59.83	57.10
Hospital profit (per hospital, million NTD)	21.30	4.59	2.72
DES price elasticity	−2.40	−2.19	−2.13
Government subsidy (million NTD)	43.97	43.97	43.97
Subsidy allocated to DES	16.38	19.69	20.79
Social surplus (CS + profit - subsidy) (million NTD)	59.45	139.90	186.29
DES utilization rate (%)	38.08	45.92	48.26
Panel B: Technology Adoption and Patient Access			
Portfolio modification probability per hospital:			
Overall (%)	43.69	35.61	36.34
Adoption (%)	27.01	25.86	25.75
Upgrade (%)	33.92	23.36	24.23
Hospital-level DES combinations	4.32	4.20	4.25
With newest generation	3.58	3.39	3.41
Proportion of newest-generation options (%)	82.87	80.68	80.42
Patients receiving newest-generation DES (%)	34.48	41.71	44.43

Table 6 presents the equilibrium implications of market structure. To mitigate potential errors from random draws, we repeat the simulation 10 times for the $N = 2$ and $N = 10$ scenarios and report the average outcomes; for the $N = 20$ case, we simulate the unique market configuration comprising all observed hospitals. Panel A demonstrates the expected pro-competitive effects: moving from duopoly to the full competitive market reduces average DES prices by approximately 19% (from 70.13 to 57.10 thousand NTD) while nearly tripling consumer surplus (from 60.81 to 175.84 million NTD). These magnitudes align with the substantial price elasticities documented in our demand estimates, confirming that market power translates directly into higher patient costs.

The producer-side outcomes reveal a distinct monotonic decline in profitability, contrasting with the inverted-U patterns often predicted in theoretical models where volume expansion may initially offset margin compression. Hospital profits fall precipitously from 21.30 million NTD under duopoly

[11] Our treatment of unobserved demand shocks in counterfactual scenarios follows a conservative approach. For hospital-manufacturer-quarter combinations observed in the data, we retain the control-function residuals from our demand estimation. For new combinations arising endogenously in the simulation (e.g., when a hospital adopts a previously unoffered brand), we examined both zero residuals and imputation via a triple fixed-effects specification. The qualitative patterns and quantitative magnitudes prove remarkably stable across these alternatives, with key outcomes differing by less than 1%. We report results based on the zero-residual specification for transparency.

to 2.72 million NTD in the fully competitive market. This trajectory indicates that the price erosion effect dominates the volume expansion effect as competition intensifies. Consequently, total social surplus—defined as consumer surplus plus hospital profits minus government subsidies—increases monotonically with competition, driven largely by the substantial gains in consumer welfare that outweigh the reduction in producer rents.

Panel B reveals the critical interplay between competition and innovation diffusion. The probability of portfolio modification—encompassing both new brand adoption and existing brand upgrades—declines from 43.7% in duopoly to approximately 36% in more competitive markets. This pattern reflects the erosion of innovation rents: in more competitive environments, the quasi-rents from offering differentiated technologies are competed away, weakening the profit incentive for costly adoption. However, this reduction in hospital-level churning does not translate into reduced patient access. Instead, the proportion of patients receiving newest-generation DES exhibits a robust upward trend, rising from 34.5% under duopoly to 44.4% in the competitive market. This occurs partly because competition lowers DES prices, and partly because having more hospitals in the market increases consumers' hospital-brand choices, even though each hospital offers a smaller and less up-to-date DES portfolio.

This result challenges the conventional view of a "central tension" where market power is necessary to fund technology diffusion. While competition indeed erodes hospitals' incentives to invest in portfolio updates (the "incentive effect"), it simultaneously enhances affordability through lower prices (the "access effect"). The data reveal that in this setting, the access effect dominates: the lower prices in competitive markets enable a broader segment of patients to access frontier technologies, more than compensating for the reduced frequency of hospital portfolio updates. Thus, competition fosters both affordability and the widespread adoption of frontier technologies.

Figure 6 decomposes these equilibrium patterns into their constituent mechanisms. Panel (a) captures the first-order welfare effects: consumer surplus rises monotonically with competition due to price reductions, while per-hospital profits decline sharply. The steepest price declines occur in the transition from duopoly to moderate competition, with diminishing effects thereafter. Panels (b) through (d) trace the innovation dynamics that underlie our main results. Panel (b) demonstrates that overall DES utilization and access to newest-generation technologies increase substantially with competition, particularly in the transition from oligopoly to moderate competition ($N < 8$). Beyond this threshold, the marginal impact of additional competitors on patient access diminishes. Panel (c) highlights the role of competition in the aggregate expansion of patient access to DES technology. While the number of hospitals increases the total variety of choices available to patients—driving the rise in overall usage—the average availability of newest-generation models at the hospital level declines. This discrepancy confirms that, while competition dampens individual hospitals' incentives to adopt and upgrade, it ensures wider patient access to DES in aggregate. Panel (d) illustrates the decline in hospitals' portfolio modification probabilities, consistent with the theoretical prediction that competition reduces the payoff from adoption and upgrades. Notably, this competitive dampening effect is most pronounced in concentrated markets ($N < 8$),




Figure 6: Market Summary for Various Number of Hospitals

with incentives stabilizing as the market becomes more fragmented. Crucially, this decline does not prevent the aggregate expansion of patient access to frontier technologies.

Together, these results illustrate how market structure fundamentally shapes not just the price and quantity of medical technology, but its vintage and quality distribution. As the number of hospitals increases, intensified price competition dominates reduced adoption incentives, leading to a net gain in consumer surplus and total welfare.

The Role of Patient Preferences for Innovation. The preceding analysis held demand parameters fixed while varying market structure. We now examine the complementary question: how do patient preferences for technological novelty shape equilibrium outcomes across different competitive environments? This question has immediate policy relevance, as information campaigns or quality reporting initiatives could potentially shift the salience of innovation attributes in patient decision-making.

To isolate this mechanism, we conduct counterfactual simulations that scale the estimated

preference parameter for newest-generation technology by a factor ζ. We consider two scenarios: setting $\zeta = 2$ doubles patients' marginal utility from accessing frontier innovations, while $\zeta = 0.5$ halves it relative to the baseline ($\zeta = 1$). This variation allows us to trace how both stronger and weaker demand-side pull for innovation propagates through the market equilibrium across our three competitive scenarios.

Table 7: Market Outcomes Under Alternative Patient Newness Preferences

	N=2 Hospitals			N=10 Hospitals			N=20 Hospitals		
Newness Preference Factor (ζ)	0.5	1 (Baseline)	2	0.5	1 (Baseline)	2	0.5	1 (Baseline)	2
Panel A: Patient and Product Outcomes									
Consumer Surplus (million NTD)	57.06	60.81	69.63	132.69	138.00	151.14	169.99	175.84	189.99
DES Utilization Rate (%)	34.37%	38.08%	45.86%	41.25%	45.92%	55.86%	43.29%	48.26%	58.54%
Newest-Generation DES Utilization Rate (%)	30.27%	34.48%	43.66%	36.69%	41.71%	52.89%	39.10%	44.43%	55.62%
Avg. DES Models Available per Hospital	4.23	4.25	4.29	4.09	4.10	4.14	4.17	4.17	4.19
Avg. Newest-Gen. Models per Hospital	3.30	3.35	3.52	3.08	3.09	3.18	3.15	3.15	3.19
Panel B: Hospital Outcomes									
Hospital Profit (million NTD)	19.20	21.30	26.27	4.27	4.59	5.29	2.57	2.72	3.04
Social Surplus (million NTD)	51.49	59.45	78.19	131.39	139.90	160.07	177.50	186.29	206.80
Avg. Patient-Paid Price (thousand NTD)	68.71	70.13	73.39	59.51	59.83	60.61	57.03	57.10	57.31
Hospital Portfolio Modification Rate (%)	42.27%	43.69%	48.02%	35.40%	35.61%	37.50%	36.34%	36.34%	36.87%
Panel C: NHI Subsidy Outcomes									
Total Subsidy (million NTD)	43.97	43.97	43.97	43.97	43.97	43.97	43.97	43.97	43.97
Subsidy Allocated to DES (million NTD)	14.75	16.38	19.78	17.65	19.69	24.06	18.61	20.79	25.33

Notes: "Hospital Portfolio Modification Rate" represents the frequency of adoption or upgrade events per hospital among hospitals where such modifications were feasible. $\zeta = 1$ corresponds to the estimated preference; $\zeta = 2$ doubles the marginal utility from the newest generation relative to the previous generation within the same brand; $\zeta = 0.5$ halves this marginal utility. All outcomes are averaged across simulations. Units are New Taiwan Dollars (NTD).

Table 7 reveals how heightened patient preferences for innovation fundamentally reshape market equilibria, with effects that vary systematically across competitive environments. The results demonstrate that while stronger demand for novelty universally accelerates diffusion, the distribution of resulting surplus—and crucially, the affordability of innovation—depends critically on market structure.

Panel A quantifies the demand-side impacts. Doubling patients' preference for technological novelty ($\zeta = 2$) substantially increases both overall DES utilization and access to frontier technologies across all market structures. The effects are particularly striking for newest-generation adoption: even in the highly competitive baseline market ($N = 20$), utilization of newest-generation DES rises from 44.4% to 55.6%. Conversely, attenuating these preferences ($\zeta = 0.5$) reduces utilization to 39.1% in the same setting. These shifts in innovation access translate directly into consumer surplus changes, though the magnitude varies with competition—consumers in more competitive markets capture a larger share of the value created (or lost) by preference shocks.

The supply-side responses documented in Panel B reveal how hospitals strategically adapt to innovation demand. Stronger preferences ($\zeta = 2$) increase portfolio modification rates (rising from 43.7% to 48.0% in the duopoly case), confirming that demand-pull mechanisms can partially offset the innovation-dampening effects of competition. Conversely, weaker preferences ($\zeta = 0.5$) lead to

a slight reduction in modification activity in concentrated markets (falling to 42.3%) while leaving competitive markets unchanged. However, pricing responses diverge sharply by market structure. In concentrated markets ($N = 2$), hospitals exploit enhanced willingness-to-pay by raising prices substantially (from 70.13 to 73.39 thousand NTD), effectively extracting rents. Conversely, when preferences are weaker ($\zeta = 0.5$), duopolists are forced to lower prices (to 68.71 thousand NTD). In contrast, competitive market prices remain essentially flat regardless of the preference shock (ranging only from 57.03 to 57.31 thousand NTD), indicating that competition forces nearly complete pass-through of value to consumers.

Panel C illuminates an important fiscal externality of innovation preferences. While total government expenditure remains fixed by design, the allocation shifts dramatically toward DES as utilization increases. The share of subsidies flowing to DES rises by approximately 20% across all market structures when preferences double, highlighting how demand-side factors can reshape public spending patterns even under budget-neutral policies.

These findings synthesize into a crucial insight for policy design: patient preferences for innovation create powerful diffusion incentives, but without sufficient competition, these preferences may paradoxically enable price increases that offset the welfare gains from better technology. This fundamental tension—between harnessing demand-pull innovation incentives and maintaining affordability—motivates our examination of targeted reimbursement mechanisms that could better align private incentives with social objectives.

5.2 Alternative Reimbursement Designs for Enhanced Innovation Diffusion

We evaluate three alternative reimbursement designs, each operating through a distinct economic channel. The first adjusts DES-specific reimbursement rates, decoupling them from the BMS benchmark to directly influence provider margins and pricing decisions. The second employs selective contracting, where the insurer negotiates wholesale discounts with specific manufacturers in exchange for exclusive reimbursement eligibility. The third introduces targeted patient subsidies that reduce out-of-pocket costs for vulnerable populations without disrupting market pricing mechanisms. These interventions offer different combinations of benefits and costs across three key dimensions: innovation diffusion, fiscal burden, and distributional equity.

Alternative Design #1: Adjusting DES Reimbursement Rate. The simplest NHI reform is adjusting the reimbursement rate for DES independently from BMS. We parameterize this through a multiplicative factor r^d applied to DES procedures, resulting in a reimbursement of $r^d \cdot r_t$ for DES while maintaining r_t for BMS. If $r^d < 1$, NHI reduces DES support from the status quo, if $r^d > 1$, NHI increases DES coverage.

Table 8 presents market outcomes under two alternative regimes: doubling the DES payment ($r^d = 2$) and halving it ($r^d = 0.5$). The results reveal a symmetric but heterogeneous pass-through of reimbursement shocks. In competitive markets ($N = 20$), doubling the reimbursement lowers patient prices by 35% (from 57.1 to 37.0 thousand NTD), driving a 17 percentage point surge in utilization. In contrast, duopolists capture a larger share of the subsidy, reducing prices

by only 20% and limiting the utilization gain to 12 percentage points. Conversely, halving the reimbursement forces hospitals to raise copayments by approximately 17% in competitive markets, contracting utilization by 8 percentage points. This symmetry confirms that hospitals function as effective pass-through entities that transmit policy-induced cost shocks to patients through price adjustments, especially in a competitive market.

Welfare outcomes exhibit a sharp trade-off between fiscal efficiency and patient access. While subsidy expansion ($r^d = 2$) generates broad surplus gains, it inflates NHI expenditure by over 50%. In contrast, the reimbursement cut ($r^d = 0.5$) yields 20% fiscal savings but constrains access. Notably, portfolio modification rates remain relatively stable under the cut (falling only 0.3 percentage points), suggesting that adoption fixed costs generate portfolio inertia, rendering technology supply less elastic than pricing to reimbursement changes.

Table 8: Market Outcomes Under Alternative DES Reimbursement Factors (r^d)

	N=2 Hospitals			N=10 Hospitals			N=20 Hospitals		
DES Reimbursement Factor	0.5	1.0	2.0	0.5	1.0	2.0	0.5	1.0	2.0
Panel A: Patient and Product Outcomes									
Consumer Surplus (million NTD)	55.44	60.81	73.78	129.71	138.00	159.75	166.69	175.84	200.08
DES Utilization Rate (%)	32.53	38.08	49.66	38.22	45.92	62.06	40.04	48.26	65.25
Newest-Gen DES Rate (%)	29.49	34.48	45.31	34.70	41.71	56.79	36.76	44.43	60.52
Avg DES Models per Hospital	4.27	4.32	4.35	4.18	4.20	4.21	4.24	4.25	4.26
Avg Newest-Gen Models per Hospital	3.56	3.58	3.69	3.39	3.39	3.41	3.43	3.41	3.43
Panel B: Hospital Profit and Pricing									
Hospital Profit (million NTD)	17.96	21.30	29.56	4.06	4.59	5.76	2.49	2.72	3.23
Avg Patient-Paid Price (thousand NTD)	77.30	70.13	56.22	69.33	59.83	40.73	67.13	57.10	36.98
Portfolio Modification Rate (%)	42.80	43.70	45.30	35.50	35.60	35.90	36.60	36.30	36.90
Panel C: Government Subsidy									
Total Subsidy (million NTD)	37.04	43.97	65.62	35.86	43.97	71.02	35.44	43.97	72.52
Subsidy Allocated to DES (million NTD)	3.82	9.09	24.15	4.24	10.26	27.96	4.45	10.78	29.64
Social Surplus (million NTD)	54.31	59.45	67.28	134.44	139.90	146.31	181.05	186.29	192.13

Notes: The table compares outcomes for $r^d = 1$ (baseline) and $r^d = 2$ (doubled DES reimbursement). Consumer Surplus, Hospital Profit, Total NHI Subsidy, and DES-Specific NHI Subsidy are reported in millions of NTD; Average Patient-Paid Price is in thousands of NTD; usage rates and portfolio modification probabilities are percentages. Aggregate choices represent the total number of hospital-product combinations offered in the market.

Alternative Design #2: Selective Contracting. Selective contracting leverages the government insurer's bargaining power to negotiate favorable terms with specific manufacturers. Unlike the broad reimbursement adjustment examined above, this approach targets specific products and manufacturers, potentially achieving more efficient outcomes by motivating manufacturers to offer discounts in exchange for exclusive insurance coverage. This mechanism has been recently used by the NHI in the coverage of Hepatitis C treatment[12], but not yet for DES or other medical

[12]Taiwan has long faced a high burden of liver cancer, with chronic viral hepatitis—including hepatitis C—as an important underlying risk factor. In late 2016, Taiwan's National Health Insurance (NHI) negotiated with manufacturers to introduce oral direct-acting antivirals (DAAs) into reimbursement beginning in 2017. In the initial

innovations.

To illustrate the idea, consider a particular form of selective contract with two complementary elements. First, the NHI negotiates wholesale discounts with chosen manufacturers—in our simulations, the two market leaders Abbott and Medtronic—reducing hospital input costs to $r^c \cdot c_{hmt}$ where $r^c < 1$ represents the discount factor. Second, the NHI grants exclusive reimbursement eligibility to contracted brands, effectively creating a two-tier market where non-contracted DES become out-of-network products that patients must fully finance.

To clarify, our goal is *not* to pursue an optimal design of selective contracts. If NHI adopts selective contracting in reality, it may use competitive auction or an expert committee to determine what brands to cover, how to solicit manufacturer discount, and whether to involve hospitals in negotiation. An optimal design of this process would require much more data beyond what we can access in this study. Rather, our goal is to illustrate that selection contracting—even in an ad doc form as we simulate—can simultaneously reduce patient costs, maintain adoption incentives, satisfy manufacturer participation constraints, and control public spending.

Table 9 presents outcomes under a representative selective contracting arrangement combining a 50% wholesale discount ($r^c = 0.5$) with baseline reimbursement rates ($r^d = 1$). The policy alleviates the double marginalization distortion, enabling a "quadruple win." In competitive markets ($N = 20$), hospitals exhibit high pass-through of input cost reductions, lowering patient prices by 41% (from 56,110 to 33,130 NTD) and expanding DES utilization by 16 percentage points (from 41.8% to 57.3%).

Crucially, the impact on innovation incentives is mediated by market competition. In the duopoly setting, selective contracting boosts hospital rents and thus catalyzes a surge in portfolio updating for targeted brands (rising from 25.5% to 41.2%). In contrast, competitive markets see only a modest increase (from 18.2% to 19.1%), as intense price competition erodes the profit margin. This suggests that selective contracting is most effective at stimulating innovation diffusion in markets where intermediaries possess significant market power.

This mechanism stands in sharp contrast to the DES reimbursement policy (Alternative Design #1), where competitive markets amplified policy effectiveness because high pass-through lowered patient prices, directly stimulating demand. In selective contracts, however, high pass-through dilutes the policy's leverage. In competitive markets ($N = 20$), intense rivalry forces hospitals to pass through the bulk of the wholesale discount to patients, leaving the hospital's own profit margin largely unchanged. Consequently, the financial incentive to incur the fixed costs of portfolio restructuring is weak. In contrast, hospitals in concentrated markets ($N = 2$) possess sufficient market power to retain a larger share of the discount as profit. This "profit retention" effect dramatically increases the margin on contracted products, creating a powerful internal incentive

round, two manufacturers agreed to a substantial price reduction—approximately from NT$2.5 million to NT$0.25 million per treatment course—whereas a third declined, highlighting how selective contracting can lower unit prices and expand treatment access while preserving firms' participation incentives. By 2025, Taiwan had nearly achieved hepatitis C elimination (Chien et al. (2021)), with estimated returns exceeding 20% (Pwu et al. (2025)). See the complete story from https://tmuhprc.tmu.edu.tw/en/%e3%80%90media-coverage%e3%80%91

for duopolists to update their DES portfolios.

The overall welfare effects confirm the efficiency of selective contracting. Consumer surplus rises by 11% in the $N = 20$ market due to lower prices and expanded access. Hospitals profit from wider margins on higher volumes, as the wholesale discounts exceed the pass-through to patients. The government maintains budget neutrality, as negotiated discounts offset volume growth. Finally, contracted manufacturers benefit from dramatic market share gains that more than compensate for per-unit price reductions.

Table 9: Market Outcomes under Selective Contracting Policy Designs

	N=2 Hospitals		N=10 Hospitals		N=20 Hospitals	
Reimbursement factor (r^d)	1 (Targeted)	1 (Targeted)	1 (Targeted)	1 (Targeted)	1 (Targeted)	1 (Targeted)
Cost factor (r^c)	1 (Targeted)	0.5 (Targeted)	1 (Targeted)	0.5 (Targeted)	1 (Targeted)	0.5 (Targeted)
Consumer-related:						
Consumer Surplus (million NTD)	59.20	73.15	131.48	149.36	168.52	187.65
% of DES usage	36.37%	49.35%	39.95%	54.97%	41.77%	57.29%
% of patients using newest generation	32.43%	45.61%	35.82%	49.21%	38.14%	52.09%
Hospital-related:						
Profit (million NTD)	14.70	22.28	4.13	5.17	2.54	2.99
Avg. Patient-Paid Price (thousand NTD)	70.46	51.12	65.30	43.15	63.00	40.32
Targeted DES	64.41	45.34	58.38	35.99	56.11	33.13
Non-targeted DES	84.99	90.53	80.50	81.88	78.31	78.89
NHI-related:						
Subsidy (million NTD)	33.72	36.67	33.34	36.23	33.25	36.24
Targeted DES	10.93	18.54	11.73	19.96	12.34	20.84
BMS	22.79	18.13	21.60	16.27	20.92	15.41
Market Structure & Dynamics:						
Total hospital-model DES choices	2301	2327	11329	11392	2292	2303
w/ newest generation	1907	1964	9139	9212	1852	1860
Portfolio Modification Probability per Hospital	19.02%	20.74%	15.07%	15.49%	15.53%	15.73%
Targeted DES	25.53%	41.18%	17.42%	18.93%	18.24%	19.07%
Non-targeted DES	14.52%	11.41%	13.26%	13.03%	13.46%	13.29%

Table 10: Preferred Direction of Policy Parameters

	NHI	Consumers	Hospitals	Manufacturers
Cost Factor, r^c	Lower	Lower	Lower	Mid-range
Reimbursement Factor, r^d	Lower	Higher	Higher	Higher

Building on these results, Table 10 summarizes directional preferences over the two policy parameters—r^c (the wholesale cost factor for targeted DES) and r^d (the reimbursement factor for targeted DES)—for each stakeholder. The NHI, seeking to curb expenditure, prefers lower r^c (greater negotiated discounts) and lower r^d (smaller per-case payments). Consumers prefer lower r^c to reduce prices through pass-through and higher r^d to increase coverage and reduce out-of-pocket payments. Hospitals, driven by margins, also favor lower r^c and higher r^d. The sharpest conflict is over r^d: the insurer's cost-minimizing preference for a lower reimbursement opposes the preferences of consumers and hospitals. By contrast, preferences over r^c are more aligned—everyone benefits from lower input costs—though the division of the gains between patients and hospitals depends on competitive conditions and pricing conduct.

For selective contracting to be feasible, targeted manufacturers must also prefer participation over the status quo. Although their costs are unobserved, their revenue under selective contracting reflects a trade-off between price and volume: deeper discounts reduce per-unit revenue but increase quantity via exclusivity and lower patient prices. Because market share expands when non-targeted brands are excluded, the revenue effect of r^c is generally non-monotonic. Manufacturers often prefer an interior discount that balances volume gains against price cuts.[13]


To characterize the joint effects of the policy levers, we simulate outcomes on a grid with $r^d \in [0.1, 1]$ and $r^c \in [0.1, 1]$ (using increments of 0.1 for both r^c and r^d shown in the figures). The left column of Figure 7 plots iso-curves for three outcomes—consumer surplus, total NHI expenditure, and the share using the newest-generation DES—for markets with $N = 2$, $N = 10$, and $N = 20$. The right column of Figure 7 plots the iso-revenue curves for targeted DES manufacturers, in the three market structures respectively, with the red line representing these manufacturers' revenue under the status quo.

Consistent with Table 10, consumer surplus increases when reimbursement is more generous (higher r^d) and wholesale costs are lower (lower r^c), corresponding to the upper-left regions of each panel. Total NHI spending falls as both levers are tightened (lower-left). Using the status quo ($N = 2$ in Table 6) as a benchmark, the contour lines identify policy combinations that weakly improve patient and hospital outcomes while keeping NHI expenditure at or below baseline. When $N = 2$, (Figure 7(a)), the status-quo reference values are consumer surplus of 60.8 million NTD, newest-DES use of 34.5%, and total NHI expenditure of 44.0 million NTD. Regions to the "north-west" of the consumer-surplus and newest-DES iso-curves and to the "south-west" of the 44.0 million NTD expenditure iso-curve yield improvements for patients and hospitals without higher public spending. This feasible area must be further restricted to the "north-east" of the red iso-revenue curve in Figure 7(b), so that the targeted manufacturers have incentives to accept the selective contract. All in all, the feasible area corresponds to the upper right of the red real line and the upper left of the green and blue dashed lines in Figure 7(b).


Similar patterns arise in more competitive markets (Figures 7(c)–(f)), though with a notable difference: the feasible "quadruple-win" region shrinks as competition increases. In the $N = 2$ market, the policy effectively leverages the substantial exclusivity rents available to duopolists, allowing a broad range of (r^c, r^d) combinations to improve outcomes. In contrast, competitive markets ($N = 10, 20$) have already dissipated much of the rent that the policy seeks to redistribute. Consequently, achieving the same simultaneous improvement for all stakeholders requires a more precise—and often more restrictive—calibration of reimbursement and discount rates.

Alternative Design #3: Patient Coupon Program. We now shift focus from supply-side intervention to demand-side subsidy. Unlike reimbursement adjustments or selective contracting—which operate through hospital margins—patient coupon program directly subsidizes DES adoption for financially vulnerable patients.


[13] In practice, the NHI could operationalize this scheme by announcing coverage for a limited set of DES brands and inviting manufacturers to bid on r^c. The participation constraint we study is a necessary condition; an auction mechanism could further improve the NHI's terms.




(a) NHI, Patient, Hospital for $N = 2$




(b) Manufacturer for $N = 2$




(c) NHI, Patient, Hospital for $N = 10$



(d) Manufacturer for $N = 10$



(e) NHI, Patient, Hospital for $N = 20$



(f) Manufacturer for $N = 20$

Figure 7: Policy Outcomes under Selective Contracting: Varying (r^c, r^d)

Figure 8 illustrates the motivation for this policy. Under the status quo ($N = 20$), we observe a steep socioeconomic gradient: DES adoption is substantially lower for the bottom income decile

(41.7%) compared to the top 5% (59.2%), highlighting a clear gap in medical accessibility. To address this, we examine two counterfactual scenarios: (1) a targeted program covering only the lowest income decile (0-10%), and (2) a broader tiered program extending coverage to the bottom 50% (0-50%). In both scenarios, we employ a progressive subsidy design that mimics the sliding-scale structure of ACA Premium Tax Credits. For the lowest income group (<10th percentile), the coupon value is set at 36,000 NTD (covering 60% of the co-payment). In the tiered scenario, this amount phases out by 6,000 NTD for each subsequent income decile: 30,000 NTD for the 10-20% group, 24,000 NTD for 20-30%, 18,000 NTD for 30-40%, and 12,000 NTD for the 40-50% group. Patients above the median income receive no subsidy.




Figure 8: Distribution of Income and DES Uptake under the Status Quo (N=20)

Table 11 reports the market impact of these interventions. As expected, coupons are highly effective in persuading targeted patients to gain additional medical access. For instance, in the 0-10% scenario, adoption among the lowest decile surges by over 28 percentage points, nearly converging with the levels of higher-income groups. Even under the broader 0-50% coverage, the program successfully lifts adoption rates for all subsidized cohorts.

While demand increases, an unintended effect may be a simultaneous increase in prices. Contrary to this concern, we find that *competitive* markets absorb the subsidy shock. As shown in Table 11, when subsidy is limited to the bottom 10% or when the market is sufficiently competitive ($N \geq 10$), hospitals find it optimal to absorb the demand expansion from the subsidized segment without raising prices, as doing so would alienate the larger, price-elastic non-subsidized population. Consequently, the portfolio modification rates remain largely unchanged in these situations. However, in concentrated markets ($N = 2$), expanding subsidy coverage to middle-income groups (0-50%) triggers more price increases and motivates duopoly hospitals to adjust their DES portfolios more frequently.

To better understand the distributional effects, Figure 9 visualizes the change in DES adoption across the income spectrum as subsidy coverage expands. Each panel corresponds to a different

Table 11: Market Outcomes of the Tiered Patient Coupon Program: 10% vs. 50% Coverage

	$N = 2$ Hospitals		$N = 10$ Hospitals		$N = 20$ Hospitals	
Statistic	0-10% Coupon	0-50% Coupon	0-10% Coupon	0-50% Coupon	0-10% Coupon	0-50% Coupon
DES Usage by Income Group (%):						
0-10% (Lowest)	61.65	60.19	67.93	67.62	70.48	70.41
10-20%	31.34	55.32	38.45	64.34	41.53	67.69
20-30%	33.49	52.37	42.12	62.79	44.49	65.43
30-40%	34.01	47.43	41.90	57.37	44.36	60.23
40-50%	36.11	44.49	46.11	56.45	48.16	58.79
50-100% (Highest)	41.13	39.53	50.39	50.18	52.82	52.83
Market Outcomes:						
Avg. Patient-Paid Price (000 NTD)	71.32	73.39	60.05	60.37	57.18	57.24
Portfolio Modification Rate (%)	20.09	21.31	15.19	15.20	15.36	15.46
Government Budget (Million NTD):						
Hospital Reimbursement	43.97	43.97	43.97	43.97	43.97	43.97
Coupon Cost	4.81	13.97	5.29	16.37	5.49	17.11
Total Expenditure	48.78	57.94	49.27	60.34	49.47	61.08


Notes: The table compares outcomes between the 0-10% Coupon Program (coupons for lowest 10%) and the 0-50% Coupon Program (coupons for lowest 50%). Coupon amounts are tiered: 36k NTD (0-10%), 30k (10-20%), 24k (20-30%), 18k (30-40%), 12k (40-50%). Income groups 50-100% receive no coupon.

market structure. The heatmaps reveal a pattern of "strategic leakage": in concentrated markets ($N = 2$), expanding coverage to middle-income groups triggers price increases that dampen adoption among higher-income, non-subsidized patients (indicated by the pink regions in the bottom row). In contrast, competitive markets ($N = 20$) facilitate a smoother expansion of access, with minimal spillover effects on ineligible populations, as competition constrains hospitals' ability to cross-subsidize or raise prices.

Regardless of market structure, patient subsidy tends to push up the NHI spending on DES, especially when the subsidy coverage is broad. As shown in Table 11, the spending increase is more conspicuous in more competitive markets because competition prevents hospitals from increasing patient-facing price, which further encourages the DES utilization of subsidized patients. Put it another way, to ensure that a demand-side patient coupon can improve equity with a limited consequence for the NHI budget, the NHI may need to limit the coupon to a small fraction of targeted low-income patients, even if the market is competitive enough to dismiss the concern of price increase.

6 Conclusion

This paper examines how hospital competition and reimbursement policy shape the diffusion of medical innovations in Taiwan's drug-eluting stent market. Our structural analysis reveals a key tradeoff: while competition effectively disciplines prices, it simultaneously erodes the surplus required to incentivize hospitals to adopt frontier technologies. Counterfactual simulations suggest that, as the number of hospitals increases, intensified price competition dominates reduced adoption incentives, leading to a net gain in consumer surplus and total welfare.



(a) $N = 2$ Hospitals (b) $N = 10$ Hospitals (c) $N = 20$ Hospitals

Figure 9: Impact of Tiered Coupon Coverage and Market Competition on DES Usage

Notes: These heatmaps display the absolute change in DES usage (in percentage points) relative to the no-coupon baseline for different income groups (rows) and coverage schemes (columns). Each column represents a cumulative expansion of eligibility: "0-10%" provides coupons only to the lowest decile, while "0-50%" covers the bottom half of the income distribution. Coupon values are means-tested, ranging from 36,000 NTD for the lowest income group to 12,000 NTD for the 40-50% group. Blue cells relate to increases in usage, while red cells indicate decreases.

Conditional on market structure, our counterfactual simulations demonstrate that selective contracting and targeted patient coupons offer promising pathways to further improve the balance of access, costs, and equity. By leveraging exclusivity to align manufacturer and hospital incentives, selective contracting can achieve a "quadruple-win", benefiting patients, hospitals, contracted manufacturers, and the government. However, the feasibility of such outcomes is contingent on market structure: the parameter space for a "quadruple-win" shrinks significantly in competitive markets, where the scarcity of exclusivity rents limits the policy's leverage.

In comparison, targeted patient coupons can effectively mitigate socioeconomic disparities in access without distorting market prices, if the program has limited coverage or the market is sufficiently competitive. Yet in these situations, they fail to stimulate broader technology adoption (the extensive margin) due to the high fixed costs of portfolio modification. Similarly, reimbursement rate adjustments across all DES models exhibit heterogeneous pass-through, with competitive markets responding more elastically than concentrated ones. Unlike selective contracting, both targeted patient coupons and DES reimbursement adjustments entail extra government spending on DES utilization. Together, these results highlight the importance of accounting for hospitals' strategic responses and market structure when designing policies to promote medical innovation diffusion.

Our findings have broader implications for healthcare markets where intermediaries control technology access. Traditional policies focusing solely on upstream R&D incentives prove insufficient when hospitals act as strategic gatekeepers. Effective policy must recognize this intermediation role and align hospital incentives with social objectives. Future research should explore several extensions: incorporating dynamic considerations of how current adoption affects future innovation by manufacturers, examining heterogeneous hospital objectives beyond profit maximization, and testing the generalizability across different medical technologies and healthcare systems. As healthcare costs continue rising globally, understanding how intermediaries influence the diffusion-affordability trade-off becomes increasingly critical for policy design.

References

Aboulafia, Gabriella, Jonathan Gruber, and Benjamin D Sommers. 2025. "The Rise and Fall (and Rise) of the Affordable Care Act: Varying Impacts on Coverage Over Time and Place." National Bureau of Economic Research Working Paper 32252.

Aghion, P., N. Bloom, R. Blundell, R. Griffith, and P. Howitt. 2005. "Competition and Innovation: an Inverted-U Relationship." *The Quarterly Journal of Economics*, 120(2): 701–728.

Agostoni, Pierfrancesco, Giuseppe G.L. Biondi-Zoccai, Gabriele L. Gasparini, Maurizio Anselmi, Giorgio Morando, Marco Turri, Antonio Abbate, Eugene P. McFadden, Corrado Vassanelli, Piero Zardini, Antonio Colombo, and Patrick W. Serruys. 2005. "Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials." *European Heart Journal*, 26(9): 881–889.

Arrow, Kenneth J. 1962. "Economic Welfare and the Allocation of Resources for Invention." In *The Rate and Direction of Inventive Activity*. 609–626. Princeton University Press.

Bangalore, Sripal, Bora Toklu, Neil Patel, Frederick Feit, and Gregg W. Stone. 2018. "Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease." *Circulation*, 138(20): 2216–2226.

Bergman, Alon, Matthew Grennan, and Ashley Swanson. 2021. "Medical Device Firm Payments To Physicians Exceed What Drug Companies Pay Physicians, Target Surgical Specialists: Study examines payments medical device firms pay to physicians." *Health Affairs*, 40(4): 603–612.

Bergman, Alon, Matthew Grennan, and Ashley Swanson. 2022. "Lobbying Physicians: Payments from Industry and Hospital Procurement of Medical Devices." National Bureau of Economic Research w29583, Cambridge, MA.

Berry, Steven T., and Joel Waldfogel. 1999. "Free Entry and Social Inefficiency in Radio Broadcasting." *The RAND Journal of Economics*, 30(3): 397.

Chandra, Amitabh, and Jonathan Skinner. 2012. "Technology Growth and Expenditure Growth in Health Care." *Journal of Economic Literature*, 50(3): 645–80.

Chandra, Amitabh, David Cutler, and Zirui Song. 2011. "Chapter Six - Who Ordered That? The Economics of Treatment Choices in Medical Care." In *Handbook of Health Economics*. Vol. 2 of *Handbook of Health Economics*, , ed. Mark V. Pauly, Thomas G. Mcguire and Pedro P. Barros, 397–432. Elsevier.

Chandra, Amitabh, Evan Flack, and Ziad Obermeyer. 2024. "The Health Costs of Cost Sharing*." *The Quarterly Journal of Economics*, 139(4): 2037–2082.

Chernew, Michael E., and Joseph P. Newhouse. 2011. "Chapter One - Health Care Spending Growth." In *Handbook of Health Economics*. Vol. 2 of *Handbook of Health Economics*, , ed. Mark V. Pauly, Thomas G. Mcguire and Pedro P. Barros, 1–43. Elsevier.

Chien, Rong-Nan, Sheng-Nan Lu, Raoh-Fang Pwu, Grace Hui-Min Wu, Wen-Wen Yang, and Chia-Ling Liu. 2021. "Taiwan accelerates its efforts to eliminate hepatitis C." *Global Health Medicine*, 3(5): 293–300.

Ching, Andrew T., Tülin Erdem, and Michael P. Keane. 2013. "Invited Paper—Learning Models: An Assessment of Progress, Challenges, and New Developments." *Marketing Science*, 32(6): 913–938.

Collard-Wexler, Allan, Matthew Grennan, and Andrew Steck. 2024. "Regulating New Product Testing: the FDA vs. the Invisible Hand." *Working Paper*.

Conley, Timothy G, and Christopher R Udry. 2010. "Learning About a New Technology: Pineapple in Ghana." *American Economic Review*, 100(1): 35–69.

Dafny, Leemore. 2005. "How Do Hospitals Respond to Price Changes?" *American Economic Review*, 95(5): 1525–1547.

Decarolis, Francesco. 2015. "Medicare Part D: Are insurers gaming the low income subsidy design?" *American Economic Review*, 105(4): 1547–1580.

Duggan, Mark, and Fiona Scott Morton. 2010. "The Effect of Medicare Part D on Pharmaceutical Prices and Utilization." *American Economic Review*, 100(1): 590–607.

Dunn, Abe, Lasanthi Fernando, and Eli Liebman. 2023. "A Direct Measure of Medical Innovation on Health Care Spending: A Condition-Specific Approach." *Health Management, Policy & Innovation*.

Dunn, Abe, Lasanthi Fernando, and Eli Liebman. 2024. "How Much Are Medical Innovations Worth? A Detailed Analysis Using Thousands of Cost-Effectiveness Studies." *working paper*.

Garthwaite, Craig, Christopher Ody, and Amanda Starc. 2022. "Endogenous quality investments in the U.S. hospital market." *Journal of Health Economics*.

Grennan, Matthew. 2013. "Price Discrimination and Bargaining: Empirical Evidence from Medical Devices." *American Economic Review*, 103(1): 145–177.

Grennan, Matthew. 2014. "Bargaining Ability and Competitive Advantage: Empirical Evidence from Medical Devices." *Management Science*, 60(12).

Grennan, Matthew, and Ashley Swanson. 2020. "Transparency and Negotiated Prices: The Value of Information in Hospital-Supplier Bargaining." *Journal of Political Economy*, 128(4): 1234–1268.

Ho, Kate, and Robin S. Lee. 2019. "Equilibrium Provider Networks: Bargaining and Exclusion in Health Care Markets." *American Economic Review*, 109(2): 473–522.

Jin, Ginger Zhe, Hsienming Lien, and Xuezhen Tao. 2025. "Top-up Design and Health Care Expenditure: Evidence from Cardiac Stents." *China Economic Review*, 93.

Kaiser, Christian, Søren Galatius, Paul Erne, Franco R Eberli, Hans Alber, Gert Richardt, Giovanni Pedrazzini, Bernhard Hornig, Ljerka Savic, Dominique Justice, et al. 2010. "Drug-Eluting versus Bare-Metal Stents in Large Coronary Arteries." *New England Journal of Medicine*, 363(24): 2310–2319.

Kandzari, David E, Laura Mauri, Jacques J Koolen, Joseph M Massaro, Gheorghe Doros, Hector M Garcia-Garcia, Johan Bennett, Ariel Roguin, Elie G Gharib, Donald E Cutlip, and Ron Waksman. 2017. "Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial." *The Lancet*, 390(10105): 1843–1852.

Kyle, Margaret K. 2007. "Pharmaceutical Price Controls and Entry Strategies." *Review of Economics and Statistics*, 89(1): 88–99.

Mankiw, N. Gregory, and Michael D. Whinston. 1986. "Free Entry and Social Inefficiency." *The RAND Journal of Economics*, 17(1): 48.

McClellan, Mark. 2011. "Reforming Payments to Healthcare Providers: The Key to Slowing Healthcare Cost Growth While Improving Quality?" *Journal of Economic Perspectives*, 25(2): 69–92.

McClellan, Mark B., David T. Feinberg, Geisinger, Peter B. Bach, Paul Chew, Omada Health, Patrick Conway, Nick Leschly, Bluebird Bio, Greg Marchand, Michael A. Mussallem, Edwards Lifesciences Corporation, and Dorothy Teeter. 2017. "Chandra." *NAM Perspectives*, 7(3).

Myerson, Rebecca, Hongwei Li, Reginald Tucker-Seeley, and Donna D McAlpine. 2021. "Marketplace subsidies associated with reduced cost sharing and lower probabilities of catastrophic health expenditures." *Health Affairs*, 40(3): 502–513.

Navarese, Eliano P, Kanmin Tandjung, Bernard E Claessen, Felice Andreotti, Mariusz Kowalewski, Malte Kelm, Niels van Royen, Stefano De Servi, Jacek Kubica, and Harm Suryapranata. 2014. "First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients." *Open Heart*, 1(1): e000064.

Nexon, David, and Stephen Ubl. 2010. "Implications Of Health Reform For The Medical Technology Industry." *Health affairs (Project Hope)*, 29: 1325–9.

Olssen, Alexander L., and Mert Demirer. 2024. "Drug Rebates and Formulary Design: Evidence from Statins in Medicare Part D." *Working Paper*.

Pakes, A., J. Porter, Kate Ho, and Joy Ishii. 2015. "Moment Inequalities and Their Application: Moment Inequalities and Their Application." *Econometrica*, 83(1): 315–334.

Pwu, Raoh-Fang, Wen-Wen Yang, Grace Hui-Min Wu, Sheng-Nan Lu, and Rong-Nan Chien. 2025. "Investing in health: Policy lessons from reimbursing direct-acting antivirals for hepatitis C in Taiwan." *Journal of the Formosan Medical Association*, 124: S141–S148. Toward Hepatitis C Elimination in Taiwan: 2025 Report.

Schumpeter, Joseph Alois. 1942. *Capitalism, Socialism and Democracy.* New York:NY: Harper & Brothers.

Skinner, Jonathan, and Douglas Staiger. 2015. "Technology Diffusion and Productivity Growth in Health Care." *Review of Economics and Statistics*, 97(5): 951–964.

Sorensen, Alan T. 2003. "Insurer-Hospital Bargaining: Negotiated Discounts in Post-Deregulation Connecticut." *The Journal of Industrial Economics*, 51(4): 469–490.

Starc, Amanda, and Ashley Swanson. 2021. "Preferred Pharmacy Networks and Drug Costs." *American Economic Journal: Economic Policy*, 13(3): 406–446.

Tebaldi, Pietro. 2025. "Estimating Equilibrium in Health Insurance Exchanges: Price Competition and Subsidy Design under the ACA." *The Review of Economic Studies*, 92(1): 1–45.

Tu, Jack V, John Bowen, Mandy Chiu, Dennis T Ko, Peter C Austin, Y He, Rheal B Hopkins, Warren J Cantor, David A Alter, Harindra C Wijeysundera, et al. 2007. "Effectiveness and safety of drug-eluting stents in Ontario." *New England Journal of Medicine*, 356(10): 1009–1019.

Wollmann, Thomas G. 2018. "Trucks without Bailouts: Equilibrium Product Characteristics for Commercial Vehicles." *American Economic Review*, 108(6): 1364–1406.

Yurukoglu, Ali, Eli Liebman, and David B. Ridley. 2017. "The Role of Government Reimbursement in Drug Shortages." *American Economic Journal: Economic Policy*, 9(2): 348–382.

Zheng, D., et al. 2024. "The Affordable Care Act and income-based disparities in health care coverage and spending among nonelderly adults with cancer." *Health Affairs Scholar*, 2(4): qxae048.

Appendix A Details on Equilibrium Computation

This appendix details the computational procedure for counterfactual equilibria. The algorithm solves a two-stage game each period: hospitals first adjust portfolios, then compete in prices. This sequential structure captures the distinction between long-run technology investments and short-run pricing decisions.

Let M_{ht} denote hospital h's portfolio in period t, $\mathcal{M}_t$ the market-wide portfolio profile, and $\mathcal{P}(\mathcal{M}_t)$ the Nash equilibrium prices given portfolios. Hospital payoffs are $\pi_{ht}(\cdot)$ net of variable costs, with fixed adjustment costs $C(M_{ht}, M_{h,t-1})$ for portfolio changes. The algorithm proceeds via iterated best responses until convergence, as detailed in Algorithm 1.

Algorithm 1 (Counterfactual Equilibrium Simulation)**.**

1. ***Initialization for period*** t***.*** *At the beginning of period* t*, each hospital observes the simulated portfolios and prices from period* $t-1$*. For the initial iteration (*$s=0$*), set each hospital* h*'s portfolio equal to its previous-period portfolio:*

$$M_{ht}^{(0)} = M_{h,t-1}.$$

2. ***Iterative best responses in portfolios.*** *For iteration* $s \geq 1$*, consider hospitals sequentially. For a given hospital* h*, take other hospitals' portfolios from iteration* $s-1$*, denoted by* $\mathcal{M}_t^{(s-1)}$*, and evaluate each feasible portfolio* M *for* h *by:*

   (a) *Solving the pricing subproblem given the candidate profile* $\big(M, \mathcal{M}_t^{(s-1)}\big)$ *to obtain the vector of equilibrium prices*

$$\mathcal{P}\big(M, \mathcal{M}_t^{(s-1)}\big).$$

   (b) *Computing hospital* h*'s operating payoff at those prices,*

$$\pi_{ht}\Big(M, \mathcal{P}\big(M, \mathcal{M}_t^{(s-1)}\big); \mathcal{M}_t^{(s-1)}\Big).$$

   (c) *Subtracting the fixed adjustment cost relative to period* $t-1$ *to form net payoff,*

$$\pi_{ht}\Big(M, \mathcal{P}\big(M, \mathcal{M}_t^{(s-1)}\big); \mathcal{M}_t^{(s-1)}\Big) \;-\; C\big(M, M_{h,t-1}\big).$$

   Update hospital h*'s portfolio to the maximizer,*

$$M_{ht}^{(s)} \;\in\; \arg\max_{M} \Big\{\pi_{ht}\Big(M, \mathcal{P}\big(M, \mathcal{M}_t^{(s-1)}\big); \mathcal{M}_t^{(s-1)}\Big) - C\big(M, M_{h,t-1}\big)\Big\}.$$

   After all hospitals have updated in iteration s*, denote the resulting portfolio profile by* $\mathcal{M}_t^{(s)}$*. If* $\mathcal{M}_t^{(s)} = \mathcal{M}_t^{(s-1)}$*, declare convergence for period* t *and proceed. Otherwise, continue to iteration* $s+1$*.*

3. ***Finalize the period-t outcome.*** *The converged profile $\mathcal{M}_t$ and the associated equilibrium prices $\mathcal{P}(\mathcal{M}_t)$ constitute the simulated market outcome for period t.*

4. ***Advance to period $t+1$.*** *Use $\mathcal{M}_t$ as the starting point for period $t+1$ and repeat the steps above until the final period.*

When the best-response procedure cycles rather than converging, we randomly select from the cycling portfolios as the equilibrium outcome. To ensure robustness, we average results across five independent simulation runs with varying initial conditions.

Appendix B Willingness to Pay and Willingness to Travel Calculation

This appendix quantifies patients' valuation of technological innovation through willingness to pay (WTP) and willingness to travel (WTT) measures. Using our demand estimates, we translate the utility gain from accessing newest-generation technology into monetary and distance equivalents that inform the welfare analysis in the main text.

Following standard discrete choice theory, WTP for the newest-generation attribute equals the ratio of its marginal utility to the marginal utility of income (negative of the price coefficient):

$$\text{WTP}_{\text{newest},i} = -\frac{\beta_{2i}}{\beta_{5i}}$$

where β_{2i} captures patient i's preference for newest-generation technology and β_{5i} is the price sensitivity parameter. Both coefficients vary with patient characteristics through the interaction terms estimated in Table 3, Column 4.

For the average patient in our sample, we compute WTP by evaluating these coefficients at the sample means (Charlson Index: 0.915, Income category: 1.007, Male: 0.766, Age: 65.304):

$$\text{WTP}_{\text{avg}} = -\frac{0.636 + (-0.029 \times 0.915) + (-0.175 \times 1.007) + (0.040 \times 0.766) + (0.001 \times 65.304)}{-0.025 + (-0.004 \times 0.915) + (0.004 \times 1.007) + (-0.004 \times 0.766) + (-0.001 \times 65.304)} \tag{8}$$

This calculation yields a WTP of approximately 5.69 thousand NTD, indicating that the typical patient values access to the newest generation at nearly 10% of the average DES price.

Analogously, WTT measures the additional distance a patient would travel to access newest-generation technology:

$$\text{WTT}_{\text{newest},i} = -\frac{\beta_{2i}}{\beta_{3i}}$$

where β_{3i} represents the disutility from travel distance. At sample means:

$$\text{WTT}_{\text{avg}} = -\frac{0.636 + (-0.029 \times 0.915) + (-0.175 \times 1.007) + (0.040 \times 0.766) + (0.001 \times 65.304)}{-0.095 + (0.005 \times 0.915) + (0.026 \times 1.007) + (-0.009 \times 0.766) + (0.0001 \times 65.304)} \tag{9}$$

This yields approximately 5.03 kilometers, a substantial distance given the dense hospital network in the Taipei metropolitan area.

These valuations reveal strong patient preferences for innovation that create powerful adoption incentives on the supply side. The magnitude of these preferences helps explain why hospitals invest in costly portfolio upgrades despite the fixed costs documented in our supply estimates, and why selective contracting policies that restrict access to certain innovations generate substantial welfare losses for excluded patients.

Appendix C Demand Elasticity Calculation

This appendix details the methodology for computing demand elasticities and documents the substantial heterogeneity that shapes our welfare conclusions. We derive individual-specific own-price elasticities for each DES alternative using the mixed logit parameter estimates reported in Table 3.

Given our linear price specification in the utility function, the own-price elasticity for individual i considering product j at time t takes the standard logit form:

$$\eta_{ijt} = \beta_i^p \cdot p_{jt} \cdot (1 - \hat{P}_{ijt}) \tag{10}$$

where p_{jt} denotes the out-of-pocket payment in thousand NTD, $\hat{P}_{ijt}$ represents the predicted choice probability from our demand model, and β_i^p captures the individual-specific price sensitivity incorporating observed heterogeneity:

$$\beta_i^p = \beta_0^p + \beta_1^p \cdot \text{Charlson}_i + \beta_2^p \cdot \text{Income}_i + \beta_3^p \cdot \text{Male}_i + \beta_4^p \cdot \text{Age}_i \tag{11}$$

The empirical distribution of calculated elasticities demonstrates uniformly elastic demand throughout the market. Individual elasticity values cluster primarily within the -3 to -1 range, with the mode occurring around -2. Such pronounced price responsiveness stems from the significant co-payments required under Taiwan's supplementary reimbursement framework, where patients bear the incremental cost above the base reimbursement rate.

Substantial heterogeneity emerges along both product and patient dimensions. Table A.1 reveals systematic variation across manufacturers, with Cordis products exhibiting markedly higher price sensitivity (mean elasticity of -2.31) relative to established market leaders such as Abbott and Medtronic (both approximating -2.0). These differential elasticity patterns illuminate why selective contracting arrangements generate asymmetric welfare effects across manufacturers, with higher-elasticity brands experiencing more pronounced quantity responses to exclusion.

Patient-level heterogeneity proves even more striking. The comprehensive evidence in Tables A.2, A.3, and A.4 establishes clear gradients in price responsiveness: elasticity magnitudes increase monotonically with comorbidity burden (Charlson Index) and patient age, while exhibiting a strong negative correlation with income level. Most notably, patients in the lowest income decile display price sensitivities approximately 50% greater than their highest-income counterparts,

highlighting the distributional burden imposed by the current cost-sharing arrangement. This systematic heterogeneity in price response provides the economic foundation for understanding how carefully designed targeted interventions—whether through selective contracting or patient-specific subsidies—can simultaneously enhance allocative efficiency and improve equity outcomes, as our counterfactual analyses demonstrate.

Table A.1: Elasticity by Brand

Brand	Mean Elasticity	Std. Dev.	Count
Abbott	-1.998	0.376	7,206
Bio Sensor	-1.964	0.365	2,002
Cordis	-2.306	0.313	3,004
Medtronic	-2.021	0.298	9,083
OTHER	-1.873	0.302	2,404
Boston Scientific	-1.861	0.395	5,662

Notes: The table reports mean own-price elasticity, standard deviation, and observation counts for each DES brand. Cordis exhibits the highest average price sensitivity (mean elasticity of -2.306), while Boston Scientific and OTHER have the least sensitive demand on average.

Beyond brand-level differences, the analysis reveals systematic variations in price sensitivity correlated with patient-specific characteristics. As detailed in Tables A.2, A.3, and A.4, patients with greater health burdens, those with lower incomes, males, and older individuals tend to exhibit more elastic demand. Specifically, Table A.2 shows a clear positive relationship between the Charlson Comorbidity Index and the magnitude of price elasticity, indicating that patients with more comorbidities are more responsive to price changes. Similarly, Table A.3 demonstrates that patients in lower income brackets are, on average, more price-sensitive than their higher-income counterparts. Finally, Table A.4 indicates that males exhibit slightly higher price sensitivity compared to females, and that price elasticity tends to increase with patient age. These demographic and health-related patterns in price responsiveness are important for understanding the distributional consequences of pricing and reimbursement policies.

Table A.2: Elasticity by Charlson Index

Charlson Index	Mean Elasticity	Count
0	-1.840	11,766
1	-2.038	13,000
2	-2.243	3,700
3	-2.422	681
4	-2.577	162
5	-2.736	52

Notes: The table shows mean own-price elasticity and patient counts grouped by Charlson Comorbidity Index. Price sensitivity increases monotonically with the Charlson Index, indicating that patients with more comorbidities are more responsive to price changes.

Table A.3: Elasticity by Income Category

Income Category	Mean Elasticity	Count
1 (Lowest)	-2.106	2,164
2	-2.077	2,540
3	-2.061	2,599
4	-2.038	3,098
5	-2.032	3,042
6	-2.000	3,017
7	-2.024	3,044
8	-1.947	3,000
9	-1.897	3,287
10 (Highest)	-1.876	3,570

Notes: This table presents mean own-price elasticity and patient counts across ten income categories. Patients in the lowest income category exhibit the highest price sensitivity (elasticity of -2.106), with a general trend of decreasing sensitivity as income rises.

Table A.4: Elasticity by Gender and Age Quartile

Panel A: By Gender		
Gender	Mean Elasticity	Count
Female	-1.910	6,758
Male	-2.024	22,603
Panel B: By Age Quartile		
Age Group	Mean Elasticity	Count
Quartile 1	-1.893	7,026
Quartile 2	-1.966	7,891
Quartile 3	-2.035	7,760
Quartile 4	-2.103	6,684

Notes: Panel A reports mean elasticity by gender, showing males (-2.024) are slightly more price-sensitive than females (-1.910). Panel B shows mean elasticity by age quartile, indicating that price sensitivity increases with age, with the oldest quartile being the most price-sensitive (-2.103).